Ireland
--:--IST
Accountability · 198 corrections logged

Corrections log

When a figure, label or claim on this site turns out to be wrong, we fix it and record it here: what was wrong, what we changed and when, and, where we have one, the check now in place so it does not happen again. Most of these were found by our own checks.

To report an error, email info@priyalifescience.com or use the contact form, and name the page and the figure. How we handle corrections is set out in our editorial standards, and how each dataset is built is explained on the methodology page. This log covers corrections from August 2026 onwards.

GMP Knowledge Hub: six 21 CFR pages

What was wrongThe pages for 21 CFR Parts 210 and 211, 820, 600 to 680, 11, 312 and 4 were labelled as the text of the regulations, but they mixed short quotations with commentary written by a third party, and left most of each regulation out.
What we changedReplaced each page with the full text of the regulation from the government's eCFR (the biologics page now holds Parts 600, 601 and 610 in full), with the date it is current to and a link to the official version. Every FDA and ICH document in the hub was rebuilt from the publisher's current official file at the same time.
To prevent itEach document is now checked word for word against the publisher's file before it is published, and the page names its source and the date it was copied.

GMP Knowledge Hub: human factors for combination products

What was wrongThe page carried FDA's February 2016 draft guidance on human factors studies for combination products, which FDA replaced with a final guidance in September 2023.
What we changedReplaced it with the final guidance, Application of Human Factors Engineering Principles for Combination Products: Questions and Answers (September 2023).

Article: Cold chain management and GDP

What was wrongThe article said temperature mapping was a fixed annual requirement; the EU GDP guidelines call for initial mapping and risk-based repeats. It said GDP inspectors come from the EMA (inspections are by national authorities such as the HPRA), gave unsourced 48 to 96 hour passive hold times, said active containers give indefinite control and presented Arrhenius calculations as the release test.
What we changedCorrected the mapping, inspection, hold-time and excursion-handling text to follow the EU GDP guidelines and the manufacturer's stability data, and removed a section and a block of questions that appeared twice. Added a list of the sources used and a dated correction note at the end of the article.

Article: Ubotica funding for orbital AI maritime intelligence

What was wrongThe FAQ named Enterprise Ireland and European space technology funds as backers, gave the round as €11 million (it was $11 million) and called Atlantic Bridge an early-stage backer. The article also made unsourced claims about US and European sales teams, a new satellite constellation, new chipsets, a Spanish facility and uses such as illegal fishing and search and rescue.
What we changedCorrected the investors and the currency, described the LMI service and the use of funds as the sources do, attributed the model count and mission record to Ubotica, and removed the unsourced claims and a section and FAQ that appeared twice. Added a list of the sources used and a dated correction note at the end of the article.

Article: Blueprints and ProvenMetal join Y Combinator

What was wrongThe article described ProvenMetal first as a benchtop X-ray system maker and later as procurement and metallurgy software; it assembles printed circuit boards and X-ray scans each board in-house. It later described Blueprints as an engineering and architectural-drafting tool; it builds AI trading tools. It also gave an unsourced acceptance rate below 1.5% and a euro conversion.
What we changedCorrected both company descriptions, added the founders' universities, the early customer interest and the terms of the Y Combinator deal, and removed the unsourced figures, a contradictory FAQ that appeared twice and a repeated closing paragraph. Added a list of the sources used and a dated correction note at the end of the article.

Article: Securing AI agents on Amazon Bedrock session

What was wrongThe article said the session was free and that places were capped, shortened the session title, and described content the AWS Startups event page does not list, such as VPCs, IAM and KMS, fine-tuning, GDPR and goal hijacking. An FAQ also wrongly said Guardrails define system prompts. Several sections appeared twice.
What we changedMatched the title, time, speakers, level and content to the AWS Startups page, removed the unsourced sections and FAQs, and added an update noting that the 9 July 2026 date has passed. Added a list of the sources used and a dated correction note at the end of the article.

Article: OOS investigations and CAPA

What was wrongThe article said retesting typically uses 5 to 7 replicates and cited FDA and MHRA guidelines for this. The FDA OOS guidance says the number of retests is set in advance in an SOP and is not adjusted according to results. A block of questions appeared twice.
What we changedRewrote the retesting passage to follow the FDA OOS guidance of May 2022, and removed the repeated questions. Added a list of the sources used and a dated correction note at the end of the article.

Article: US IRA and EU pricing policies

What was wrongThe article described an EU condition to launch in all 27 member states within two years, an earlier proposal superseded by the December 2025 provisional deal. It gave imprecise IRA timelines, called the negotiation exemption regulatory exclusivity, presented industry's R&D-shift argument as fact and said me-too drugs were no longer viable. One section appeared three times.
What we changedAdded the provisional deal's protection periods, corrected the IRA timelines (eligibility at 7 years for small molecules and 11 for biologics), noted the first negotiated prices from 1 January 2026, attributed the R&D argument to industry and removed the repeated copies. Added a list of the sources used and a dated correction note at the end of the article.

Article: Media fill validation

What was wrongThe article called an aseptic process simulation the primary method for proving an aseptic process is sterile; EU GMP Annex 1 says it should not be the primary means of validation. It gave fixed incubation conditions, called for genetic sequencing, and gave frequency and failure answers that did not match Annex 1. A repeated block of questions had an inaccurate growth-media answer.
What we changedCorrected these points to follow Annex 1, noting that incubation conditions must be justified and validated, and removed the repeated questions. Added a list of the sources used and a dated correction note at the end of the article.

Article: Freeze-drying technology and cycle development

What was wrongThe article gave unsourced fixed figures for residual moisture (below 2%) and cycle length (24 to 72 hours), said freeze-drying allows room-temperature storage, overstated the case against spray drying and said cake defects compromise sterility. A section appeared twice.
What we changedReplaced the fixed figures with references to product specifications, said some products can be stored without refrigeration, softened the spray-drying answer, said cake defects may lead to batch rejection and removed the repeated section. Added a list of the sources used and a dated correction note at the end of the article.

Article: HR Duo funding for UK expansion

What was wrongThe article called Puma Growth Partners German (it is a UK firm), gave the UK share of the sales pipeline as over 70% (it is 75%) and presented Enterprise Ireland as a co-lead. It also claimed 80% automation of routine HR tasks, AI and machine-learning plans, proprietary algorithms and a London compliance team, none of which is sourced.
What we changedCorrected these points, added sourced figures on revenue growth, margin and the use of funds, and removed the unsourced claims, including two sections that appeared twice. Added a list of the sources used and a dated correction note at the end of the article.

Article: AbbVie and Merck KGaA acquisitions

What was wrongAt publication the article said AbbVie had completed its deal and called Merck KGaA's acquisition successful; AbbVie had agreed to buy Apogee on 22 June 2026 and Merck KGaA agreed to buy Bio-Techne on 25 June, and neither had closed. It also named gene therapies as a target and made unsourced analyst and regulatory claims.
What we changedCorrected the status of both deals, added the deal terms and updates (AbbVie completed on 3 September), removed the unsourced claims and a section that appeared three times, and fixed a heading typo. Added a list of the sources used and a dated correction note at the end of the article.

Article: Fieldfisher GTM Live Roundtable in Dublin

What was wrongThe article called the event the B2B Scaling Roundtable; it was the GTM Live Roundtable. It described an agenda the organisers never published, covering venture capital, ESOPs, KEEP, IP and GDPR, and the FAQ gave the wrong venue and an invented registration route. Some text was repeated.
What we changedCorrected the title and rewrote the article from the event listings, covering the sales panel, keynote, legal briefing and waitlist, named the hosts given on the Luma page and treated the event as past. Added a list of the sources used and a dated correction note at the end of the article.

Article: Data integrity and ALCOA+ in the QC laboratory

What was wrongThe article said the HPRA issues warning letters (only the FDA does), defined accurate data as data free from edits rather than data whose changes are documented, and called data integrity the primary target of inspections. A section and FAQ appeared twice.
What we changedCorrected these points, based the FDA and MHRA framing on the FDA's 2018 data integrity guidance, and removed the repeated section. Added a list of the sources used and a dated correction note at the end of the article.

Article: CroíValve Series B expansion

What was wrongThe article said BGF led the round (no lead was named) and the FAQ said specialist VCs and Enterprise Ireland led it. It gave a Series B total that included grants, said the device anchors inside the heart (the anchor sits in the superior vena cava), mentioned CE Mark trials, and gave an unsourced figure of 4 million patients and hiring plans.
What we changedCorrected the investors, the totals, the device name and the TANDEM II study description, noted that the device is investigational, and removed the unsourced lines and repeated sections. Added a list of the sources used and a dated correction note at the end of the article.

Article: Computer systems validation and GAMP 5

What was wrongThe article called GAMP 5 the global standard and the industry standard; it is industry guidance, and the legal requirements are in EU GMP Annex 11 and 21 CFR Part 11. It did not mention the 2022 second edition. A section and FAQ appeared twice.
What we changedDescribed GAMP 5 as guidance, added the second edition's focus on critical thinking and computer software assurance, and removed the repeated section. Added a list of the sources used and a dated correction note at the end of the article.

Article: ASCO 2026 pancreatic cancer data

What was wrongThe article described the pancreatic cancer result as a first-line combination immunotherapy with a 4.2-month gain; the ASCO 2026 Plenary result was RASolute 302, daraxonrasib in previously treated metastatic disease. A 58% lung cancer result named no trial and could not be traced, and claims about mRNA vaccines and fast-track reviews had no source.
What we changedReplaced the pancreatic section with the RASolute 302 results (median overall survival of 13.2 against 6.7 months), changed the title to drop lung cancer, and removed the untraced and unsourced claims and repeated sections. Added a list of the sources used and a dated correction note at the end of the article.

Article: ADC and GLP-1 obesity pipelines

What was wrongThe FAQ said oral GLP-1 drugs were still in Phase III, but the Wegovy pill launched in the US in January 2026 and Foundayo was approved on 1 April 2026. The article also made unsourced claims about research budgets, deal sizes, ADC plants in Cork and Dublin and GLP-1 fill-finish by Novo Nordisk and Lilly in Ireland.
What we changedUpdated the oral GLP-1 section and FAQ, removed or softened the unsourced claims, and removed a section that appeared twice. Added a list of the sources used and a dated correction note at the end of the article.

Article: AI as the operating system for biopharma R&D

What was wrongThe article said AI had halved recruitment times and cut preclinical timelines from five years to under eighteen months, without a source. It named Pfizer Ringaskiddy and Lilly Kinsale as using AI for crystallisation, and said the HPRA and FDA had been forced to update their guidelines. Some sections appeared three times.
What we changedReworded the figures as aims, removed the company names, cited the EMA reflection paper of September 2024 and the FDA draft guidance of January 2025, and removed the repeated copies. Added a list of the sources used and a dated correction note at the end of the article.

Article: Top universities in Ireland

What was wrongThe article gave undated QS rankings and unsourced University of Limerick figures (2,000 placements; UL says over 2,600), said TU Dublin specialises in STEM, and made unsourced claims about UCD's student numbers and ranking, 35,000 international students and Trinity being the most prestigious. An FAQ was repeated.
What we changedDated the QS 2027 rankings to 18 June 2026, added the Trinity and UCD positions, matched the UL, TU Dublin and Galway details to their own pages, and removed the unsourced claims and the repeated FAQ. Added a list of the sources used and a dated correction note at the end of the article.

Article: Irish startup ecosystem funding guide

What was wrongThe guide gave the Seedcorn prize fund as €280,000 (it is €800,000), attributed Co-Fund NI to InterTradeIreland, and misstated the Enterprise Ireland HPSU criteria and investment terms, the LEO feasibility grant rates, the SURE look-back (six years, not four) and the R&D tax credit rate. It also named a Kerry angel syndicate we could not find.
What we changedCorrected each of these points from the official sources, including the R&D tax credit rising to 35% under the Finance Act 2025, and removed the unsourced claims. Added a list of the sources used and a dated correction note at the end of the article.

Article: Ireland's multinational GDP distortion

What was wrongThe article dated the tariff-driven export surge to late 2025 and said fourth-quarter GDP soared; it fell 3.8%, and the surge was in the first quarter of 2025. It attributed an unsourced comment to Eurostat, gave an unsourced export figure, called 2015's 26.3% a quarterly figure (it was annual growth) and misdescribed GNI*.
What we changedCorrected the timing from CSO data, gave the full definition of GNI* and added an update with the later revisions to first-quarter 2026 GDP. Added a list of the sources used and a dated correction note at the end of the article.

Article: Alcohol reduction app funding

What was wrongThe article said the Health Research Board funds the app; it is funded by the Sláintecare Integration Innovation Fund and led by HSE Health and Wellbeing. It described alcohol treatment cases as rising steadily when they rose by less than 1% in 2025, added a reworded sentence to the Minister's quote and made unsourced claims about the app's design and data security.
What we changedCorrected the funding source and the treatment figures, trimmed the quote to the Minister's two published sentences, removed the unsourced claims and changed Behavioral to Behavioural in the headline. Added a list of the sources used and a dated correction note at the end of the article.

Article: All-island public health knowledge hub

What was wrongThe article reworded the second sentence of Minister Chambers' quote, and the FAQ gave the wrong project partners and left the Northern Ireland Executive out of the PEACEPLUS funders. The article also described research areas for the hub, such as stress, cognitive ageing and chronic disease, that no source mentions.
What we changedRestored the verbatim quote, corrected the partners and funders, and replaced the research-focus claims with the stated aims of the project. Added a list of the sources used and a dated correction note at the end of the article.

Article: Addiction Counsellors of Ireland strategic plan

What was wrongThe article attributed to Minister Murnane O'Connor words she did not say, and quoted John Devlin with words we could not find in any source. It also misdescribed where CORU regulation of addiction counsellors stands and listed plan goals, such as dual diagnosis and lobbying for funding, that are not in the plan.
What we changedReplaced the Minister's quote with her published words, removed the untraced quote, added the launch date of 6 June 2026, and corrected the plan goals and CORU status to match the plan. Added a list of the sources used and a dated correction note at the end of the article.

Article: UK £85 million obesity care projects

What was wrongThe article said the NIHR runs the programme with industry co-investment; it is up to £50 million from government and up to £35 million from Eli Lilly, delivered by Innovate UK. It gave the NHS cost of obesity as £6.5 billion (it is more than £9 billion a year), listed unsourced projects and framed the programme as GLP-1 clinical trials.
What we changedCorrected the funders, delivery body and cost figure, replaced the project list with the five projects the government named, removed the clinical-trial framing and an unsourced Irish section, and changed the headline to match. Added a list of the sources used and a dated correction note at the end of the article.

Article: Life science PR setup guide

What was wrongThe guide said industry codes prohibit employees from liking or sharing posts. The HPRA rule is that prescription-only medicines may not be promoted to the public in any media, and the PMCPA's guidance says likes and reposts may count as dissemination.
What we changedReplaced the claim with the HPRA rule and the PMCPA guidance, fixed stray formatting characters and softened a claim about wire services. Added a list of the sources used and a dated correction note at the end of the article.

Article: Viewpoint on Irish pharma and carbon leakage

What was wrongThe headline called Ireland's pharma sector immune to carbon leakage; the Central Bank study says it is less exposed. The article credited the study to the journalist who reported it rather than its Central Bank authors, misstated the 0.06% finding and the Central Bank's wording, and made unsourced claims about on-site renewable energy and the CSRD.
What we changedChanged immune to less exposed in the headline, credited the study to its Central Bank authors, restored the Central Bank's wording and replaced the unsourced claims with the reasons the study gives. Added a list of the sources used and a dated correction note at the end of the article.

Article: UK looks to Catalonia for clinical trials

What was wrongThe article did not give the conference dates or its source, and referred to the US FDA where the source spoke of regulatory peers in the US. FAQ answers described a Catalan model and a UK adoption plan that no source describes, and the FAQ appeared twice.
What we changedAdded the conference dates (9 and 10 June 2026) and named Clinical Trials Arena as the source, corrected the FDA reference, replaced the FAQ answers and removed the duplicate. Added a list of the sources used and a dated correction note at the end of the article.

Article: Pharmaceutical regulatory update 2026

What was wrongThe article misdated the EU pharma deal and treated it as final; it is a provisional agreement of 11 December 2025 awaiting adoption. It misstated the protection periods, called Operation TrialBlazer an FDA decentralised-trials initiative (it is HHS-wide), said the FDA now mandates Diversity Action Plans (the requirement is not yet in force) and claimed FDA digital inspections without a source.
What we changedCorrected these points, including the 8 years of data protection plus 1 year of market protection capped at 11 years, and disclosed that the NSF session cited is promoted content. Added a list of the sources used and a dated correction note at the end of the article.

Article: Overcoming middle management resistance to AI

What was wrongThe article attributed figures and conclusions, including a saving of up to 30%, to McKinsey, Deloitte, PwC, EY and KPMG. We could not trace any of them to a published study.
What we changedRemoved the attributions and figures and reworded the points as neutral advice. Added a dated correction note at the end of the article.

Article: 2026 obesity power rankings

What was wrongThe article called the orforglipron launch highly anticipated, though it had been approved as Foundayo on 1 April 2026. It did not say the FENIX ranking dates from April 2026 or that it is sponsored content, misstated details for Roche, AstraZeneca, Amgen and Boehringer Ingelheim, and carried an unsourced line on Kailera. The FAQ appeared twice.
What we changedAdded the approval and the date and sponsored nature of the ranking, corrected the company details to match it, and removed the Kailera line and the duplicate FAQ. Added a list of the sources used and a dated correction note at the end of the article.

Article: NICE recommends Libtayo for cervical cancer

What was wrongThe headline and text said Libtayo was recommended in England and Wales, for about 90 women in the UK, and routinely available. NICE's final draft guidance covers England, for around 90 adults a year, through the Cancer Drugs Fund first. The article also claimed Ireland's NCPE was evaluating the drug, and FAQ answers gave an untraced survival figure and incomplete eligibility.
What we changedCorrected the scope in the headline and text, added the Cancer Drugs Fund route, removed the NCPE claim, corrected the FAQ answers from NICE and trial figures and removed a duplicated FAQ block. Added a list of the sources used and a dated correction note at the end of the article.

Article: Navigating Ireland's pharma dependency

What was wrongThe excerpt and opening said pharmaceuticals account for 20% of Ireland's GDP, which no source supports. The FAQ said pharma makes up over one-third of goods exports; the CSO figure for 2025 is 53.2%. An FAQ claim about corporation tax surpluses going into reserve funds was not verified.
What we changedReplaced the GDP claims with the CSO export share, corrected the FAQ figure and removed the reserve-fund claim. Added a list of the sources used and a dated correction note at the end of the article.

Article: Irish Universities Association Strategy 2026-2030

What was wrongThe article quoted a launch statement on universities and competitiveness that is not in the IUA release, the strategy page or the strategy itself. It also claimed the IUA wants competitive PhD stipends, gave FAQ answers on GxP education and pharma curricula not in the strategy, and listed members without DCU and Maynooth. Two sections were duplicated.
What we changedRemoved the quote, added the publication date of 25 June 2026, rewrote the industry and funding sections and FAQ answers to the strategy's own commitments, listed all seven member universities and removed the duplicated and unsourced sections. Added a list of the sources used and a dated correction note at the end of the article.

Article: Helus Pharma US$50 million offering

What was wrongA section and two FAQ answers described Helus Pharma as an immunology and oncology company preparing marketing submissions; it develops serotonergic agonists for depression and anxiety. The article also misstated the use of proceeds and partner and adviser details, and said the offering was expected to close (it closed on 25 June 2026). The FAQ block appeared three times.
What we changedReplaced the section with the use of proceeds from the closing release, corrected the FAQ answers and the descriptions of people, added an update on completed enrolment and the new chief executive, and removed the duplicate FAQ blocks. Added a list of the sources used and a dated correction note at the end of the article.

Article: Penthrox paediatric licence in the UK

What was wrongThe contraindications and interactions did not match the UK summary of product characteristics; respiratory depression was missing and the interactions were loosely worded. The article attributed an unsourced statement to the MHRA and Galen, gave overseas paediatric use without a source, and described the MAGPIE trial vaguely.
What we changedReworded the contraindications and interactions to the summary of product characteristics, attributed the overseas use to NHS patient information, and described the MAGPIE trial and the regulatory route for the paediatric approval. Added a list of the sources used and a dated correction note at the end of the article.

Article: From farming to pharma history

What was wrongThe article claimed, without sources, that pharma is about 20% of GDP, that 19 of the top 20 companies are in Ireland, a 99% literacy rate, that more than half of workers hold advanced degrees, and €15 billion of biopharma investment from the IDA. It gave an outdated population of 5.3 million and garbled facts about AbbVie, Lilly, Pfizer and Gilead.
What we changedRemoved the unsupported claims and corrected the population (5.46 million), export share and company facts to match CSO, IDA Ireland and company sources. Added a list of the sources used and a dated correction note at the end of the article.

Article: LillyDirect launch in the UK

What was wrongThe article described the UK LillyDirect service as a platform connecting patients with online doctors, with temperature-controlled shipping guarantees and NHS alignment; it is a dispensing and delivery service for private prescribers. It presented a paraphrase as a quote, called LillyDirect a primary driver of US sales and said diabetes therapies were included, when only Mounjaro was at launch.
What we changedRewrote the section on how the UK service works from trade press reports, turned the paraphrase into reported speech, corrected the FAQs and removed an unsourced closing section. Added a list of the sources used and a dated correction note at the end of the article.

Article: Egypt and Ireland industrial cooperation talks

What was wrongThe article and FAQ described an industrial cooperation agreement with joint ventures in the Suez Canal Economic Zone, academic exchanges, regulatory alignment and state research grants. Reports of the meeting describe talks only. A second, unsourced FAQ set appeared twice, and the ambassador's words were overstated.
What we changedRemoved the section and the duplicate FAQ sets, rewrote the remaining FAQ from a news report of the 24 June 2026 meeting and restored the ambassador's words. Added a list of the sources used and a dated correction note at the end of the article.

Article: Are Irish pharma workers the highest paid in Europe?

What was wrongThe article gave an unsourced Swiss pay premium of 15% to 25%, an unsourced claim about UK pay after Brexit and an unsourced count of top global pharma companies in Ireland. Its last section listed Switzerland as a lower-salary market, contradicting its own verdict.
What we changedRemoved or softened the unsupported figures, used the IDA Ireland count of more than 90 pharma companies, fixed the contradiction and added the 2026 higher-rate tax threshold of €44,000. Added a list of the sources used and a dated correction note at the end of the article.

Article: WorkEqual profile

What was wrongThe article left out WorkEqual's origin as Dress for Success Dublin and its 2021 rebrand, misquoted its vision statement and campaign themes, and misdescribed the WorkAbility programme. It gave unverified staff and trustee biographies, governance details, a figure of about 200 volunteers and a Grow Remote partnership we could not confirm.
What we changedCorrected the history, vision, themes and programme details from published sources, and removed the unverified biographies, details and claims. Added a list of the sources used and a dated correction note at the end of the article.

Article: H1 2026 pharma M&A surge

What was wrongThe article called PwC's count of US deals a global figure, misspelled Arcellx as Arcelix and valued the deal at about $8.2 billion (it is about $7.8 billion), misstated the Centessa and Tubulis values, said Merck's Terns deal was in oral GLP-1 and MASH (it is oncology), and said deals were closing when some still awaited approval.
What we changedCorrected these points, and removed unsourced claims about Lilly's deal count and an AI time saving of up to 30%. Added a list of the sources used and a dated correction note at the end of the article.

Article: Europe medicine pricing warning

What was wrongThe article called Stefan Oelrich a leading voice within EFPIA; he is its President. It went beyond what he told Reuters, including a claim that he named Eli Lilly, Pfizer and Boehringer Ingelheim. It also said the EU pharma package cuts data protection from eight to six years; the December 2025 provisional deal kept eight years.
What we changedCorrected his title, limited his remarks to the Reuters report and updated the pharma package section and table. Added a list of the sources used and a dated correction note at the end of the article.

Article: Eli Lilly Limerick and Kinsale expansion

What was wrongThe article gave the Limerick jobs as over 200 and over 450; Lilly says 150 new jobs and 450 in total. It said production would start in late 2026 (Lilly says 2026), misdescribed what the Kinsale expansion supports, and made unsourced claims about therapy areas, validation status, bioreactors, renewable electricity and the size of the investment in Irish history.
What we changedCorrected the jobs, timing and Kinsale details (diabetes and obesity medicines), replaced the sustainability claims with Lilly's figures and removed the unsourced claims. Added a list of the sources used and a dated correction note at the end of the article.

Article: US tariff probe into German drug pricing

What was wrongThe article described the probe as covering German pharmaceutical imports; it covers German drug pricing. It gave unsourced statements from USTR and German and EU officials, said German makers enjoy unregulated prices in the US, speculated about retaliatory tariffs and Commission countermeasures, and repeated its FAQ section.
What we changedReplaced the unsourced statements with what USTR, Chancellor Merz and Health Minister Warken said, added the comment deadline and hearing dates, and removed the speculation and the duplicate FAQ. Added a list of the sources used and a dated correction note at the end of the article.

Article: Status Yellow high temperature warning guide

What was wrongThe article said heatstroke starts at 39.5°C (the HSE says 40°C or above), did not match Met Éireann's warning details, and gave unsourced advice on drinking 2 to 3 litres a day, cold showers, caffeine and protein. It also gave 999 as the only emergency number.
What we changedCorrected the heatstroke threshold and the warning details (maximums above 27°C, night minima above 15°C, all 26 counties), added 112 as an emergency number and removed the unsourced advice. Added a list of the sources used and a dated correction note at the end of the article.

Article: Roche Clarecastle site sale

What was wrongThe article listed on-site utilities, links to Shannon Airport and IDA Ireland, the scale of the remediation and a nine of the top ten figure, none of which is in reports of the sale. It said environmental liabilities had been removed, though remediation is ongoing, and its FAQ answers did not match the reported facts. The FAQ appeared twice.
What we changedRemoved the unsourced claims, used Cushman and Wakefield's own description of the site, rewrote the FAQ to the reported facts and removed the duplicate. Added a list of the sources used and a dated correction note at the end of the article.

Article: Building a pharma personal brand on LinkedIn

What was wrongTwo sections showed broken code instead of content. The guide told readers to enable LinkedIn Creator Mode, which was removed in March 2024, said without a source that Ireland manufactures 13 of the world's top 15 medicines, and gave an invented 60% inspection statistic and an unsourced salary claim.
What we changedRestored the two sections as plain content, updated the Creator Mode advice, replaced the medicines claim with a CSO export figure and removed or softened the unsourced claims. Added a list of the sources used and a dated correction note at the end of the article.

Article: US MFN and IRA pricing and Ireland

What was wrongA table estimated pharmaceuticals at about 38% to 45% of Irish exports to the US, which conflicts with CSO data: pharmaceuticals made up €58 billion of €72.6 billion in 2024. The article also claimed aggressive stockpiling in 2023 and 2024 without a source, and presented Ed Schoonveld's views without attribution.
What we changedReplaced the estimated rows with the CSO figure, removed the stockpiling claim and attributed the views to Ed Schoonveld's Pharmaceutical Commerce article, using his own words. Added a list of the sources used and a dated correction note at the end of the article.

Article: Pharma pledges of $500 billion in US investment

What was wrongThe article did not give the main reason Reuters reported for the investments, the threat of US tariffs, or each company's published commitment. It made unsourced claims about the therapy areas of R&D spending, state-of-the-art biologics plants and thousands of high-skilled jobs.
What we changedAdded the tariff threat and the commitments of Lilly, Pfizer, AstraZeneca and Roche, and removed the unsourced claims. Added a list of the sources used and a dated correction note at the end of the article.

Article: Global biopharma layoff tracker

What was wrongThe report gave an unsourced total of over 22,000 jobs cut in 2025, and said BioNTech was scrapping planned expansions in Singapore; it is closing its Singapore site along with three German sites. It also misdescribed the enGene, Neumora, Takeda and Bayer cuts and made unsourced claims about activist investors.
What we changedReplaced the total with BioSpace's count of just over 23,000 people affected in the third quarter of 2025 alone, and corrected the company descriptions to match company and news reports. Added a list of the sources used and a dated correction note at the end of the article.

Article: Eisai £48 million UK packaging hub

What was wrongThe article said the Hatfield site would handle oncology medicines and provide serialisation and FMD compliance, mentioned Irish and Dutch hubs and over 100 jobs, and gave a US dollar figure. None of this is in Eisai's announcement. The serialisation section and an FAQ block appeared twice.
What we changedRemoved these claims, added the 17 June announcement date, the conditions on the government's manufacturing fund support and the jobs figure reported from the Office for Life Sciences, and removed the repeats. Added a list of the sources used and a dated correction note at the end of the article.

Article: Regulatory affairs expertise on LinkedIn

What was wrongThe guide told readers to enable Creator Mode, retired by LinkedIn in 2024, referred to EUnetHTA joint clinical assessments (they now run under the EU HTA Regulation) and treated the EU pharmaceutical reform as in force. It named the MSL Society credential CMSL (it is MSL-BC), listed a certification with no awarding body and cited an unverifiable reference.
What we changedCorrected or removed these items and other unsupported claims, and repaired a broken certification table. Added a list of the sources used and a dated correction note at the end of the article.

Article: LinkedIn for medical science liaisons

What was wrongThe guide gave unsourced statistics (over 70% of physicians, 3x more likely to be recognised, best posting times), said a professional photo brings 21x more views (LinkedIn says up to 21x for any photo), named the credential CMSL rather than MSL-BC, overstated code-of-practice rules, quoted unnamed MSLs and cited a non-existent reference.
What we changedRemoved the unsourced statistics and quotes, attributed the photo figure to LinkedIn, corrected the credential and references, and reworded the code table to match the IPHA Code and PMCPA guidance. Added a list of the sources used and a dated correction note at the end of the article.

Article: US-Iran peace deal and Irish pharma

What was wrongThe article gave gas and jet fuel figures without attribution, described shipping reroutes with the wrong geography, quoted an unnamed supply chain director, and made unsupported claims about central banks and deferred investment. Since publication, the June deal has collapsed.
What we changedAttributed the energy figures to the BBC and the export figure to the CSO, removed the quote and the unsupported claims, and added an update that the June deal later collapsed. Added a list of the sources used and a dated correction note at the end of the article.

Article: Laprophan completes Rivopharm acquisition

What was wrongThe article said Laprophan took an initial 60% stake in late 2025 and then full control; October 2025 was the Moroccan Competition Council notice of the planned 60% deal, which gives joint control with Piero Poli. It called the business generic and claimed German production, therapeutic areas, an African angle and a transatlantic platform without sources.
What we changedCorrected the deal history, added the 17 June announcement date and portfolio figures from the announcement, and removed the unsourced claims and repeated FAQ blocks. Added a list of the sources used and a dated correction note at the end of the article.

Article: Jazz Pharmaceuticals and AbCellera research deal

What was wrongThe headline and text called it an $820 million deal. AbCellera receives $56 million upfront for two programmes, $28 million when a third starts and up to $792 million per programme in option and milestone payments. An analyst projection was unsupported, and the article called the platform AI-powered and listed partners not in the announcement.
What we changedCorrected the headline and terms from the announcement, removed the unsupported lines and added quotes from both companies. Added a list of the sources used and a dated correction note at the end of the article.

Article: J-Pharma and Uniphar nanvuranlat Phase III trial

What was wrongThe article said Uniphar manages trial logistics, packaging, distribution, European sites and expanded access; none of this is in the companies' announcement, and the registry says there is no expanded access. It also said the FDA authorised the path and described the Part A design and comparator loosely.
What we changedDescribed Uniphar Development's actual role, corrected the trial design from registry entry NCT07265674, added the announcement date and removed the expanded-access section. Added a list of the sources used and a dated correction note at the end of the article.

Article: New US tax rules and Irish pharma

What was wrongThe article said ASU 2023-09 requires country-by-country disclosure; it requires separate disclosure of taxes paid in each jurisdiction that accounts for at least 5% of the total. It said named companies' payments to Irish Revenue had drawn US lawmakers' attention, left out the 15% EU tariff rate and the 15% Pillar Two rate, and overstated the OBBBA changes.
What we changedCorrected these points, added the dates of the April 2026 tariff proclamation and the Fiscal Council figures, and removed the unsupported claims about named companies. Added a list of the sources used and a dated correction note at the end of the article.

Article: The 47% graduate job market problem

What was wrongThe article said 47% of employers had slashed roles and that nearly half the entry-level market had vanished; in the IrishJobs survey, 47% of recruiters said they had cut graduate and entry-level roles. The FAQ treated it as a graduate underemployment rate, and the article gave 83% where the published figure is more than 80%.
What we changedCorrected the finding in the summary, text and FAQ, added the survey date and sample, and attributed the drivers to IrishJobs. Added a list of the sources used and a dated correction note at the end of the article.

Article: Jazz and PharmaMar Zepzelca trial setback

What was wrongThe article described the failed trial as a first-line maintenance combination study; it was the Phase 3 LAGOON study in second-line small cell lung cancer. A later section wrongly said the results were positive, with a statistically significant survival gain. The FAQ made unsupported territory claims and appeared three times.
What we changedAdded the LAGOON design and results from Jazz's release, the status of the accelerated approval and the 2025 first-line approval, and removed the false section, the territory claims and the repeated FAQ blocks. Added a list of the sources used and a dated correction note at the end of the article.

Article: European Biotech Act 2026

What was wrongThe article dated the Council conclusions to May 2025 (they were adopted in May 2024), paraphrased the conditions for the SPC extension wrongly and gave an incorrect jobs figure. It said EuropaBio and EFPIA welcomed the Act, gave unsourced civil society positions and confused the title of the EPRS briefing with a Médecins Sans Frontières article.
What we changedCorrected the dates, the four SPC conditions, the jobs figure (more than 900,000 in 2022) and the industry and civil society positions, and fixed the briefing citation. Added a list of the sources used and a dated correction note at the end of the article.

Article: EU Pharma Package and Critical Medicines Act

What was wrongThe article said both laws were finalised; they were politically agreed on 11 December 2025 and 12 May 2026 and await formal adoption. It said breakthrough orphan medicines keep 11 years of exclusivity, overstated the antimicrobial voucher rules and misdescribed the Critical Medicines Act procurement, joint procurement and stockpiling rules. It also cited unverified author names.
What we changedCorrected these points, including the voucher limits and the five Member States needed for joint procurement, and fixed the source citations. Added a list of the sources used and a dated correction note at the end of the article.

Article: Enterprise Ireland record exports

What was wrongThe article presented 14% growth to €13.16 billion as life sciences exports; that figure covers advanced manufacturing, construction and life sciences together, and Life Sciences and HealthTech was €3.34 billion. It named the wrong main export markets, made unsourced claims about CDMOs and trade missions, and repeated its FAQ three times.
What we changedCorrected the division name and breakdown, stated the year (2025) and the overall 8% growth, corrected the market figures and kept one corrected FAQ. Added a list of the sources used and a dated correction note at the end of the article.

Article: Council mandate on biotech innovation

What was wrongAn added section and FAQ said the Council mandate covers clinical trials, ATMPs, funding for biotech clusters and fee reductions. The directive covers genetically modified micro-organisms and organ processing only.
What we changedReplaced the section and FAQ with three questions drawn from the Council release. Added a list of the sources used and a dated correction note at the end of the article.

Article: CCPC study of the retail pharmacy market

What was wrongThe article presented a market study as an investigation into price-fixing that could lead to fines. It claimed Irish over-the-counter and generic prices are higher than elsewhere in the EU and that inert consumers let pharmacies keep prices high, and presented the CCPC's preliminary concerns as findings. The FAQ appeared three times.
What we changedChanged the headline and text to describe a market study, noted that the CCPC cannot impose remedies through one, added the timeline to a final report in summer 2027 and kept one sourced FAQ. Added a list of the sources used and a dated correction note at the end of the article.

Article: Breckenridge duloxetine recall

What was wrongThe article said over 375,000 bottles were recalled (the FDA total is about 374,000) and that the impurity exceeds daily intake limits, rather than the FDA's recommended interim limit. It gave an unsourced cause, routine stability testing, and said patients must return lots, although this is a retail-level recall. An FAQ block appeared twice.
What we changedCorrected the bottle counts, the impurity wording, the start date and the classification from FDA enforcement reports, and removed the repeated FAQ. Added a list of the sources used and a dated correction note at the end of the article.

Article: Avectas, CCRM and OmniaBio

What was wrongThe article called a platform evaluation a landmark collaboration that would move Avectas' technology directly into clinical and commercial manufacturing. It speculated about what the evaluation covers, made unsourced CRISPR and virus-free claims, and gave unsourced FAQ answers. The FAQ appeared twice.
What we changedDescribed the agreement as an evaluation in the release's terms, corrected the platform and CCRM descriptions from the sources and kept one corrected FAQ. Added a list of the sources used and a dated correction note at the end of the article.

Article: Rare disease delays and clinical trial growth in Ireland

What was wrongThe article gave no source or comparison for the 801-day wait, attributed IPHA's statement to patient groups, misstated the Denmark comparison and the 213-day measure, and cited an invented joint report, 12-month set-up times and a National Clinical Trials Office. Its FAQ said set-up takes 9 to 12 months and appeared more than once.
What we changedAdded the IQVIA data source and comparison figures, corrected the measures, replaced the unsourced section with IPHA's five proposed reforms and kept one sourced FAQ. Added a list of the sources used and a dated correction note at the end of the article.

Article: Canada-Ireland partnership

What was wrongThe article said trade had grown 150%; the release says nearly 150%. It made unsourced claims about OpenText jobs, Smurfit Westrock's role in pharma supply chains and the aims of AI cooperation, and promised large life science investments, when the visit's life science outcomes were two memorandums of understanding.
What we changedCorrected the trade figure, removed the unsourced claims and rewrote the summary and excerpt to describe the agreements. Added a list of the sources used and a dated correction note at the end of the article.

Article: Novo Nordisk Athlone expansion

What was wrongAdded sections described Athlone as a sterile fill-finish and injectable pen plant with over 350 new permanent roles and cold-chain shipping; it is a tabletting facility for oral GLP-1 treatments. The article also made unsourced market and sustainability claims, and a cold-chain section appeared twice.
What we changedReplaced the added sections with sourced text on the site, its products, jobs and timeline, and attributed the Wegovy reference to the trade press. Added a list of the sources used and a dated correction note at the end of the article.

Article: Medtronic acquires Scientia Vascular

What was wrongThe article said 1.9 million neurons are lost every second during a stroke (it is every minute), said Medtronic is legally and operationally headquartered in Galway, and gave outdated Irish medtech figures. It credited a Medtronic stroke ranking to the wrong body and made unsourced claims about market size, Medtronic's Galway site and Irish stroke centres.
What we changedCorrected the headquarters wording and the statistics, using Ibec's figures for Irish medtech, removed the unsourced claims and listed only the sources actually used. Added a list of the sources used and a dated correction note at the end of the article.

Article: Medicine pricing and supply agreements

What was wrongThe article did not give the signing date and gave an unsourced reimbursement delay of over 400 days. It described savings, off-patent price cuts and investment in tracking that the agreements do not set out, and claimed sponsors must hold higher safety stocks and notify the HPRA six months ahead. A section appeared three times.
What we changedAdded the 4 March 2026 signing date and the IPHA figure that 86% of medicines exceeded 180 days in 2025, described the agreements' actual financial and supply measures, and removed the unsourced claims and repeated copies. Added a list of the sources used and a dated correction note at the end of the article.

Article: Creating a LinkedIn profile with AI

What was wrongThe guide said LinkedIn allows up to 50 skills (the limit is 100), gave an invented figure for 70% of shortlist decisions, called one profile field the most searched and gave best posting times without a source. The profile-photo figure was not attributed to LinkedIn.
What we changedUpdated the skills limit, attributed the photo figure to LinkedIn and removed the unsourced claims. Added a list of the sources used and a dated correction note at the end of the article.

Article: Beneluxa and US pricing pressure

What was wrongThe article misdescribed the Beneluxa statement, which does not name the US, misdated and misdescribed the UK-US deal, and misstated the German savings package and Lilly's investment change. It presented an unverified quote as direct speech, misstated Albert Bourla's reason for Pfizer's position and made unsourced claims about secret talks and a race to the bottom.
What we changedCorrected the statement, the UK-US deal of 1 December 2025, the German package (€16.3 billion in 2027 through higher rebates) and the Lilly figures, changed the quote to reported speech and removed the unsourced claims. Added a list of the sources used and a dated correction note at the end of the article.

Article: EU-India free trade agreement

What was wrongThe article described the EU-India agreement as already in place; negotiations concluded on 27 January 2026, and signature and ratification are pending. It added words to the Consul General's remarks and made unsourced claims about GxP regulatory alignment, counterfeiting and a clinical-trial framework.
What we changedClarified the status with an update on the Commission's proposals to the Council, cut the remarks back to his words and replaced the unsourced claims with the intellectual property chapter as the Commission describes it. Added a list of the sources used and a dated correction note at the end of the article.

Article: US and Irish healthcare costs

What was wrongThe article said PwC named three primary cost drivers (it names five) and misdescribed its 2027 projection. It gave unsourced Irish premium rises of over 10 to 15% a year and a list of insurer reasons, and overstated claims about GLP-1 drugs and Sláintecare.
What we changedCorrected the PwC description, replaced the premium figure with the Health Insurance Authority's 10.6% average increase for 2025 and toned down the overstated claims. Added a list of the sources used and a dated correction note at the end of the article.

Article: Emerging pharma companies in Ireland

What was wrongThe article gave an invented €150 million round for LetsGetChecked, said FIRE1 had completed pivotal trials (it raised money to complete one), gave Luminate Medical a $17 million round and an FDA breakthrough designation, misdescribed Deciphex and gave ProVerum's Series B as €73 million (it was $80 million). The €491.3 million figure was undated.
What we changedCorrected the funding rounds, partners and clinical status of each company, removed an unverified ProVerum leadership line and dated the venture capital figure to 2024. Added a list of the sources used and a dated correction note at the end of the article.

Article: Seven new Rinn research centres

What was wrongThe article said the centres are funded through Science Foundation Ireland; the funder is Research Ireland. It listed research areas, such as digital therapeutics, green chemistry and climate technology, that are not among the seven centres' areas, and called the investment one of the largest in the nation's history.
What we changedCorrected the funder and the research areas, corrected the FAQ answers on funding and partners and replaced the unsourced claim with Research Ireland's own wording. Added a list of the sources used and a dated correction note at the end of the article.

Article: AQL vs RQL sampling plans

What was wrongThe Frequently Asked Questions section appeared three times. We found no factual errors.
What we changedRemoved the two repeated copies. Added a list of the sources used and a dated correction note at the end of the article.

Article: LinkedIn strategy for small pharma firms

What was wrongThe article said LinkedIn newsletters guarantee visibility. LinkedIn says subscribers get a notification and an email when a new edition is published.
What we changedReworded the passage to match LinkedIn Help. Added a list of the sources used and a dated correction note at the end of the article.

Article: Energy footprint of connected laboratories

What was wrongThe article gave unsourced energy figures per task, device and workstation, said Ollama loads a model only during inference (it keeps models in memory for five minutes by default), and described Priya LifePDF as zero-carbon with 100% data privacy. Stray backslashes showed on the page.
What we changedRemoved the invented figures, corrected the Ollama description, replaced the LifePDF claims with a plain description of in-browser processing and fixed the stray characters. Added a list of the sources used and a dated correction note at the end of the article.

Article: Lunch and Learn at ENGINE, Limerick

What was wrongThe article gave a start time of 12:30 (the Eventbrite listing says 12:00 to 2:00 PM), said registration was through an Innovate Limerick portal rather than Eventbrite, and listed session topics and regional claims we could not confirm. A section and FAQ appeared twice.
What we changedCorrected the time and registration route, removed the unconfirmed topics and claims and the repeated section, and added a note that the event has taken place. Added a list of the sources used and a dated correction note at the end of the article.

Article: MedTech clusters and local value chains

What was wrongThe article gave unsourced turnaround times, claimed device parks offer pre-certified shared cleanrooms, said the HPRA approves devices (it does not) and called ALCOA+ an FDA guideline. It also said Priya LifePDF gives instant compliance and produces PDF/A files.
What we changedRemoved or softened the unsourced claims, referred to change control under the EU MDR and ISO 13485, and removed the LifePDF claims. Added a dated correction note at the end of the article.

Article: Ireland's life science shift from manufacturing to R&D

What was wrongThe article described a National Life Science Innovation Strategy (2026) with pillars and 2030 targets, published by the Department, IDA Ireland and SFI. No such document existed; the first National Life Sciences Strategy was still being drafted. It also made unsourced claims about lab vacancy rates and spin-outs relocating, and said Priya LifePDF stamps carry metadata and produce PDF/A files.
What we changedReplaced the strategy section with what the Department of Enterprise, Tourism and Employment has published, added its job and export figures and removed the unsourced and LifePDF claims. Added a list of the sources used and a dated correction note at the end of the article.

Article: EU AI Act, EHDS and Irish life sciences

What was wrongThe article gave wrong EHDS and AI Act dates, said autonomous clinical decisions are a prohibited practice and that batch release AI is high-risk, invented Annex 11 software categories and named the wrong bodies for Ireland's health data permits. It gave unsourced export statistics and an outdated claim about Claude Pro training settings.
What we changedCorrected the dates (EHDS in force from 26 March 2025, AI Act high-risk rules delayed under a provisional deal of 7 May 2026), the risk examples and Ireland's planned Health Data Access Body, and replaced the statistics with Department of Enterprise figures. Added a list of the sources used and a dated correction note at the end of the article.

Article: Multi-agent AI workflows in clinical trials

What was wrongThe article said administration takes over 40% of trial time and attributed this to the Health Research Board, which does not support it. It cited HPRA guidelines on AI validation rather than the draft EU GMP Annex 22, said consumer AI tools violate GDPR, and said Priya LifePDF is GxP-compliant, adds dated signature metadata to stamps and produces PDF/A files.
What we changedRemoved the unsourced figure and attribution, referred to the draft EU GMP Annex 22, softened the GDPR statements and removed the LifePDF claims. Added a list of the sources used and a dated correction note at the end of the article.

Article: LinkedIn SSI score guide

What was wrongThe guide said the Social Selling Index controls the reach of posts and is LinkedIn's definitive algorithmic ranking score; LinkedIn does not say this. It also gave an unsourced threshold of below 60 and unsourced top 10% and top 1% bands.
What we changedRemoved these claims, labelled the score bands as our own rough guide and added LinkedIn's note that a high score does not always reflect a salesperson's effectiveness. Added a list of the sources used and a dated correction note at the end of the article.

Article: AI tools pricing guide for life science

What was wrongThe plan and model names were out of date for June 2026. The guide gave outdated information on Claude's training settings and web search, claimed one tool had the lowest hallucination rate, gave other unsourced figures, misdescribed the FDA and EU AI Act positions and made unsupported claims about Priya Life Science's own tools and development.
What we changedRelabelled the API price tables as older models, pointed to the providers' current pricing, corrected the Claude, FDA and EU AI Act descriptions and removed the unsourced and unsupported claims. Added a list of the sources used and a dated correction note at the end of the article.

Article: Inside Fierce Summit 2026

What was wrongThree sections added after the original post, on digital health trends, biotech incubation and an FAQ, described CareSight as a clinical remote-monitoring platform for chronic disease patients, which contradicts the post, and attributed themes to the summit that we could not confirm.
What we changedRemoved the three added sections and left the founder's own account unchanged. Added a list of the sources used and a dated correction note at the end of the article.

Article: GMP document status stamps

What was wrongThe article placed document control rules in Section 4 of Annex 1; they are in Chapter 4 of the EU GMP Guide. It listed document control as an ICH Q10 system element, which it is not, presented stamps as a regulatory requirement, and made unsourced claims about inspection findings and Part 11.
What we changedChanged the title and wording to say the rules require approved, current and identifiable documents, named the four ICH Q10 elements, removed the unsourced claims and noted that a stamp is a visual mark, not an approval or electronic signature. Added a list of the sources used and a dated correction note at the end of the article.

Article: GMP document stamp tool

What was wrongThe article said the stamp tool gives compliance with GDPR, EU GMP Annex 1, 21 CFR Part 11 and HPRA rules, and that it verifies identity, keeps an audit trail and connects to LIMS. The tool only marks a copy's status. It also cited the FDA's superseded Quality System Regulation for medical devices.
What we changedReplaced the compliance claims with what the tool does and does not do, removed the invented features and updated the reference to the FDA's QMSR, in effect since 2 February 2026. Added a list of the sources used and a dated correction note at the end of the article.

Article: Biology and conservation of river turtles

What was wrongThe article said, citing the IUCN, that over 60% of turtle species are threatened; Stanford and colleagues (2020) found more than half of 360 species threatened. It also claimed, without sources, almost 100% female hatchling ratios and millions of hatchlings released over the past decade.
What we changedCorrected the threatened-species figure and its source, and removed or softened the unsourced claims. Added a list of the sources used and a dated correction note at the end of the article.

Article: EU GMP Annex 1 for sterile manufacturing

What was wrongThe article gave the Grade A airflow guidance value as 0.45 m/s (Annex 1 gives 0.36 to 0.54 m/s), misstated the effective dates and called the 2022 revision the most comprehensive in over 20 years. It made unsourced claims about inspection reports, interview questions and hiring, and listed AbbVie Sligo, which makes drug delivery devices, as a sterile site.
What we changedCorrected the airflow figure, the effective dates (25 August 2023, and 25 August 2024 for one clause) and the revision history, removed the unsourced claims and removed AbbVie Sligo from the list. Added a list of the sources used and a dated correction note at the end of the article.

Article: Eli Lilly's Limerick investment and pharma careers

What was wrongThe article said Lilly invested over €2 billion in Limerick (it is $2 billion), that the site will employ over 1,000 people (it is 450) and that it will make Mounjaro on fill-finish lines; it will make biologic active ingredients such as monoclonal antibodies. It also called this the largest pharma investment in Irish history and gave unsourced salary ranges.
What we changedCorrected the investment, jobs and products in the title and text, and removed the unsourced claims. Added a list of the sources used and a dated correction note at the end of the article.

Article: Companies building future health teams in Ireland

What was wrongThe article placed Abbott's FreeStyle Libre production in Donegal and Sligo (it is Donegal and Kilkenny), said Lilly Limerick makes Mounjaro, linked Roche's closed Clarecastle plant to current work, used outdated names for Janssen and Nuance DAX, and cited an IDA FutureHealth 2025-2030 strategy that does not exist. It also gave unsourced salaries and forecasts.
What we changedCorrected the company details, replaced the strategy with IDA's Adapt Intelligently strategy, changed the title and removed the unsourced salary ranges, forecasts and hiring claims. Added a list of the sources used and a dated correction note at the end of the article.

Article: LinkedIn profile fixes for Irish pharma

What was wrongThe article gave unsourced statistics (78% of recruiters, 8x and 21x figures), said LinkedIn headlines are limited to 60 characters, which they are not, and said Open to Work can be used without alerting your current employer. LinkedIn says it cannot guarantee that recruiters at your company will not see the status.
What we changedRemoved the statistics, corrected the headline description and the Open to Work advice using LinkedIn Help's wording, and softened other unsupported claims. Added a list of the sources used and a dated correction note at the end of the article.

Article: Iran conflict and Ireland's pharma industry

What was wrongThe article gave unsourced cost figures, up to €1,000 per day per truck and up to €5,000 per shipment, credited to unnamed Irish logistics operators, and unsourced 12 to 24 hour detours and losses of millions of euros. It also attributed a shortage list to Think Global Health without its own caveats.
What we changedReplaced the figures with Think Global Health's fall in Gulf air-cargo capacity and the Freightos rate rises reported by RTÉ and Reuters, and added Think Global Health's note on medicine stockpiles. Added a list of the sources used and a dated correction note at the end of the article.

Article: Plant-derived cannabinoid APIs

What was wrongThe article placed Dunbar Pharma's Monksland site in County Westmeath (it is in County Roscommon), said dronabinol is approved for certain chronic pain conditions, and said the European Pharmacopoeia had begun monographs for purified cannabinoids. It also gave an unsourced market forecast of 52 billion dollars by 2034 and unverified biographical details.
What we changedCorrected the location, the two FDA-approved uses of dronabinol and the Cannabis flower monograph, and removed the forecast, the unverified details and an expired image link. Added a list of the sources used and a dated correction note at the end of the article.

Article: Ireland's pharmaceutical export decline in 2026

What was wrongThe article blamed pandemic-era demand, a post-pandemic inventory correction and logistics stockpiles; the reported cause was front-loading ahead of expected US tariffs in early 2025. It said pharma exports to the US fell 61% (chemicals and pharmaceuticals to the US fell 81.3%), got the import partner order wrong and attributed unsourced points to the OECD, UN Comtrade and Eurostat.
What we changedReplaced the explanations with the reported cause, corrected the US figure and the partner order, and removed the unsourced attributions. Added a list of the sources used and a dated correction note at the end of the article.

Article: Xeolas Pharmaceuticals Baldoyle facility

What was wrongThe article said Enterprise Ireland backed the facility, that it replaced contract manufacturing Xeolas had used since its founding, and that the company would use it to expand into Asia-Pacific and the Americas. The Enterprise Ireland release says none of these things. The article also described the facility and the products Pedippi and Bonasol in terms the release does not use.
What we changedRemoved the unsupported claims and now describe the facility, Pedippi and Bonasol in the words of the Enterprise Ireland release. Added a list of the sources used and a dated correction note at the end of the article.

Article: Jazz Pharmaceuticals exchangeable senior notes

What was wrongThe article said the proceeds would go to refinancing, R&D and acquisitions; Jazz's release says general corporate purposes. It said the share repurchases were funded from the proceeds (they were funded from cash on hand), named Jazz Pharmaceuticals as the issuer rather than Jazz Investments I Limited, and said the offering was oversubscribed and would add to earnings, which the release does not say.
What we changedCorrected the use of proceeds, the repurchase funding, the issuer and the settlement terms, removed the unsupported claims, and noted that the offering totalled 1.25 billion dollars after the option was exercised. Added a list of the sources used and a dated correction note at the end of the article.

Article: China Chunlai Education and Dublin Business School

What was wrongThe headline and text said the Hong Kong Stock Exchange had granted a waiver delaying China Chunlai's shareholder circular to 31 October 2026; we found no source for this. The article also said the deal needed no investment screening, but it was notified to the Department of Enterprise, Tourism and Employment, which confirmed on 30 July 2026 that no review was needed.
What we changedRewrote the headline and article to report only the sourced facts of the agreement to buy Dublin Business School from Kaplan for 127.5 million dollars (about HK$1 billion), and removed the unsourced details. Added a list of the sources used and a dated correction note at the end of the article.

Article: SK Biopharmaceuticals licenses opakalim

What was wrongThe article treated the 245 million dollars of assumed obligations as owed to Knopp Biosciences; it is up to 185 million dollars to Knopp on US and EU approval plus up to 60 million dollars for future Kv7 programmes. It also called the royalty outside the US global and gave unannounced filing and launch dates, Japan milestones and indications.
What we changedCorrected the milestone split, the royalty terms and the data timing, removed the unannounced dates, markets and indications, and described the deal as a licence throughout. Added a list of the sources used and a dated correction note at the end of the article.

Article: Irish companies in the Deloitte EMEA Technology Fast 500

What was wrongThe article did not say this was the 2025 edition of the list, announced in August 2026. It called the result a record, said the Irish average growth matched the EMEA average (it was 1,016.48% against 1,024.47%), described sectors that Deloitte does not use, and listed only four of the five Northern Ireland companies.
What we changedCorrected the summary, opening and FAQ, and added Halo Technologies to the Northern Ireland list. Added a list of the sources used and a dated correction note at the end of the article.

Article: Ireland reconsiders its nuclear energy ban

What was wrongThe article credited the 23% data centre figure to EirGrid (it is a CSO figure) and gave the 2015 share as under 5% (it was 5%). It attributed to the Taoiseach words he did not say, cited a 43%/28% poll we could not trace, and gave a bill stage, a 2032 forecast, a reactor size and build times we could not source.
What we changedCorrected the source and the figures, replaced the quote with what the Taoiseach said and the poll with the Irish Examiner poll (39% for, 37% against), described the CRU connection policy correctly and removed the unsourced statements. Added a list of the sources used and a dated correction note at the end of the article.

Article: Greece and Poland urge the Irish EU Presidency

What was wrongThe article called the Critical Medicines Act a proposal, although the Council and Parliament reached a provisional agreement in May 2026. It presented separate Greek and Polish ministry statements to Euractiv as a joint approach, cited an unsourced figure of over 70% for active ingredients from India and China, and listed requests, such as tax incentives and stockpiles, found in no source.
What we changedRewrote the summary and sections to report what each ministry told Euractiv, and removed the unsourced proposals and import figure. Added a list of the sources used and a dated correction note at the end of the article.

Article: FedEx Life Sciences unit

What was wrongThe article placed FedEx's European Life Science Center in Amsterdam; it is in Veldhoven. It named SenseAware as the monitoring service, where FedEx names FedEx Surround, and gave overlapping temperature bands, equipment, team names and regional divisions that appear in no source.
What we changedCorrected the location and the monitoring service, described the Veldhoven facilities (-80 °C to +25 °C) as FedEx does, and removed the unsourced details. Added a list of the sources used and a dated correction note at the end of the article.

Article: Piramal Pharma and Yapan Bio

What was wrongThe article said Piramal's first investment in Yapan Bio, in December 2021, was a 33.33% stake; it was 27.78%, for ₹101.77 crore. It rounded the consideration for the new stake, which Piramal's release gives as ₹76.09 crore ($7.96M), and added details about Genome Valley, expansion plans, management and ADC timelines that we could not source.
What we changedCorrected the figures, described Yapan Bio's capabilities as Piramal and BioProcess International do, and removed the unsourced details. Added a list of the sources used and a dated correction note at the end of the article.

Article: WuXi Biologics single-use biomanufacturing

What was wrongThe article gave an unsourced figure of more than 2,000 single-use batches at a 99.5% success rate; the company reports more than 300 batches at 98% since 2022. It dated the 46 inspections and 1,800 audits from 2017 (they are totals at the end of 2025), presented 3.5 months to PPQ as normal (6 months is typical) and overstated the WuXiUP productivity gain.
What we changedReplaced the figures with the company's own, corrected the timelines and the WuXiUP figure (5 to 15 times), and removed the unsourced TrueSite, MFG7 and PatroLab details. Added a list of the sources used and a dated correction note at the end of the article.

Article: Phoenix Equity Partners and Medmark

What was wrongThe headline and text gave a deal value of about 70 million euros. No published announcement gives one: the value was not disclosed. The article also read as a completed deal, although it is subject to regulatory approval, and named advisers, an earlier acquisition, a job title and technology plans that the announcements do not support.
What we changedRemoved the deal value from the headline and text, added that the deal is subject to regulatory approval, and removed the unsupported details. Added a list of the sources used and a dated correction note at the end of the article.

Article: William Fry, PerkinElmer and SimoTech

What was wrongThe article said PerkinElmer had acquired SimoTech and that the deal had closed, when only an agreement had been signed, on 11 August 2026; completion followed on 3 September 2026. It called Pat Desmond SimoTech's founder (the sources call him CEO) and gave adviser roles, offices, leadership plans and industry claims that William Fry and PerkinElmer did not publish.
What we changedCorrected the deal status and Pat Desmond's title, cut the adviser and company details back to what William Fry and PerkinElmer published, and removed the unsourced claims. Added a list of the sources used and a dated correction note at the end of the article.

Article: TMC Pharma Services and tranScrip

What was wrongThe article described a strategic acquisition and left out that TMC bought the business and assets of tranScrip from administrators and receivers appointed on 14 August 2026, with about 45 staff moving to TMC. It paraphrased Simon Estcourt rather than quoting his published words, and gave unsourced figures, including over 1,000 associates in more than 70 countries.
What we changedChanged the headline to say TMC bought the tranScrip business and assets after administration, quoted Simon Estcourt's published words, and corrected or removed the unsourced figures (LDC gave more than 900 associates in 2022). Added a list of the sources used and a dated correction note at the end of the article.

Article: Irish pharma export volatility after stockpiling

What was wrongThe article put the export surge in late 2025; CSO data show the record was in Q1 2025 (€87.4 billion). It dated the 35% and 61% falls to early 2026 rather than January 2026, presented stockpiling as the CSO's explanation when it is commentary, and made unsourced claims about Eli Lilly investment, GLP-1 demand, the Central Bank and analyst forecasts.
What we changedCorrected the timing, dated the falls to January 2026 with the CSO values, labelled the stockpiling explanation as commentary, rebuilt the table on CSO figures and removed the unsourced claims. Added a list of the sources used and a dated correction note at the end of the article.

Article: Dixon Technologies guarantee to Lenovo Ireland

What was wrongThe headline said Dixon secured a 220 million dollar corporate guarantee; Dixon issued it. The article gave no disclosure date, used an unsourced rupee conversion, said the filing reported no immediate cash impact (it says no immediate adverse impact), and made unsourced claims about Lenovo Ireland's role, Padget's Noida facilities, components and credit ratings.
What we changedChanged the headline to say Dixon issues the guarantee, added the 14 August 2026 disclosure date, used the filing's wording and removed the unsourced claims. Added a list of the sources used and a dated correction note at the end of the article.

Article: Rinn Pharma & Biopharma and NordicPharmaTrain

What was wrongThe quote in the article had no attribution and ran beyond the published words of Professor Damien Thompson. The article said Rinn had formally joined the consortium (it is one of three new associated partners), named the funder as the Nordic Research Council (it is NordForsk) and gave 12 Irish partner universities (it is UL plus 11 research performing organisations).
What we changedAttributed the quote to Professor Thompson and cut it to his published words, corrected Rinn's status, the funder and the partner count, and removed unsourced claims and a currency error in a heading. Added a list of the sources used and a dated correction note at the end of the article.

Article: Ireland's €93.8 billion non-EU pharma exports

What was wrongThe article credited the €93.8 billion figure to UN COMTRADE and the CSO; it comes from Eurostat, is for 2025 and covers extra-EU exports including the UK. It called Ireland the largest net exporter rather than, in Eurostat's words, the largest extra-EU exporter, and gave a table of destination values with no source.
What we changedCorrected the source and the wording, and removed the destination table and other unsourced figures and claims. Added a list of the sources used and a dated correction note at the end of the article.

Article: Women in Pharma Awards 2026

What was wrongThe article did not name the organiser, Business River, and read as fresh news, although the winners were first reported in May 2026. Aoife Callan's quote ran past her published words and her title was shortened. The article also made unsourced claims about the size of the sector and the impact of the winners' work.
What we changedNamed the organiser, noted when the winners were first reported, cut the quote back to Aoife Callan's published words with her full title, and removed the unsourced claims. Added a list of the sources used and a dated correction note at the end of the article.

Article: President Trump's September visit to Ireland

What was wrongThe article called Donald Trump a former US President; he is the President. It treated proposed 10%-20% universal tariffs as current, although the Supreme Court struck down the IEEPA tariffs on 20 February 2026. It gave out-of-date AmCham Ireland figures and an unsourced 1,000-strong delegation, protocol talks and US investment figure.
What we changedCorrected his title, the tariff position and the AmCham Ireland figures, removed the unsourced claims, and added an update on the visit. Added a list of the sources used and a dated correction note at the end of the article.

Article: US pharmaceutical tariffs and Ireland

What was wrongThe article gave Section 301 as the legal basis of the branded pharmaceutical tariffs; they are under Section 232, set on 2 April 2026, with tiered rates including 15% for EU products. It said the 61% fall in January 2026 was in exports to the US (it was in all pharmaceutical exports) and quoted BioPharmaChem Ireland in words we found in no source.
What we changedCorrected the legal basis, the rates, the generics announcement and the export figures, and removed the untraced quotes and other unsourced claims. Added a list of the sources used and a dated correction note at the end of the article.

Article: AI and Ireland's over-budget health IT projects

What was wrongThe article gave the cost of responding to the 2021 cyberattack as 58 million euro; the Comptroller and Auditor General gives about 51 million euro for 2021. It used an older cost estimate for the national electronic health record, made unsupported claims about the children's hospital opening date, PPARS and optimism-bias rules, and described FDA guidance that covers medical-device software as general guidance.
What we changedCorrected the cost, added the newer estimate of up to 3 billion euro over 10 years, removed the unsupported claims, narrowed the description of the FDA guidance and replaced press reports with the primary documents. Added a list of the sources used and a dated correction note at the end of the article.

Article: AI governance and the Zurich compliance summit

What was wrongThe article listed speakers and companies that no longer appear on the organiser's programme, including Bayer, Amarin, Pharma Integrity and GCO Global. It gave an out-of-date title for one speaker, misspelt Newport Pharmaceuticals, named members of the organiser's staff, and made promotional claims about the organiser, the city and enforcement.
What we changedRemoved the speakers and companies no longer on the programme and the staff names, corrected the title and the company name, and toned down the promotional claims. Added a list of the sources used and a dated correction note at the end of the article.

Article: Real-time data trackers for clinical trials

What was wrongThe article described our data trackers as open source. They are free to use, but the code is not published. It also implied that all our clinical trials trackers use ClinicalTrials.gov; the Europe tracker uses the EU Clinical Trials Information System (CTIS).
What we changedChanged open source to free and now name the data source of each clinical trials tracker. Added a dated correction note at the end of the article.

Article: Launching pharmaceutical products in Europe

What was wrongThe article said the EU Joint Clinical Assessment dossier should be finished six months before the marketing application is submitted. That cannot happen, because the assessment scope (PICO) is set after the application is filed. It also made unsourced claims about lead times and placebo data, and an unsourced statement about free pricing in Germany.
What we changedCorrected the timeline, added the 2028 and 2030 assessment dates and EFPIA data on access times, and removed or reworded the unsourced claims. Added a list of the sources used and a dated correction note at the end of the article.

Article: Anthropic and biopharma

What was wrongThe headline and text framed Anthropic's work in biopharma as a 100-day sprint, which is not an Anthropic term. The article described the Coefficient Bio acquisition as announced when it was only reported, listed features and uses not in the Anthropic, Bristol Myers Squibb and Genmab announcements, and carried an out-of-date comparison table and an inaccurate image caption.
What we changedChanged the headline to Anthropic's 2026 Push into Biopharma and Drug Discovery, removed the sprint framing, the unsupported features, the table and the caption, and now describe each announcement in its own terms. Added a list of the sources used and a dated correction note at the end of the article.

Article: Highest-paying automation roles in Irish biomanufacturing

What was wrongThe salary and contract rate figures in the article were higher than those in published 2026 recruiter guides, and it claimed a 35% salary premium for these roles that no source supports. It also made unsupported claims about talent shortages and particular sites.
What we changedReplaced the pay figures with the ranges in the HERO and Morgan McKinley 2026 guides and removed the 35% premium and the other unsupported claims. Added a list of the sources used and a dated correction note at the end of the article.

Article: Rent costs and biopharma investment in Ireland

What was wrongThe rent figures in the article did not match official data. It also said 25% of international candidates decline job offers, and described relocation packages, housing partnerships, counties named for IDA investment and industry-body policy positions, none of which we could source.
What we changedReplaced the rents with the RTB Rent Index for Q4 2025 (for example €2,232 a month in Dublin and €1,755 nationally) and removed the unsourced claims. Added a list of the sources used and a dated correction note at the end of the article.

Article: Using Priya Life Science as a data tracker

What was wrongThe article said the Europe clinical trials tracker uses ClinicalTrials.gov; it uses the EU Clinical Trials Information System (CTIS). It also said our sourcing portal shows companies' compliance history and that recruiters can post and manage vacancies on the site. Neither is true: the hiring dashboard is filled automatically from job boards.
What we changedCorrected the data source, removed the two claims, described the recruiter features as they are and toned down promotional wording. Added a dated correction note at the end of the article.

Article: Daily rate vs salary in Irish pharma contracting

What was wrongThe article gave day rates of €550 to €1,200, well above HERO's 2026 contract rate benchmarks (a national average of €556 a day). It gave PRSI as 4%; it is 4.2%, rising to 4.35% from 1 October 2026. It left out the 11% USC rate on self-employed income over €100,000, and made unsourced tax, pension and mortgage claims.
What we changedReplaced the rates with HERO's benchmarks, recalculated the worked example and labelled its figures as illustrative, corrected PRSI and USC, and removed the unsourced claims. Added a list of the sources used and a dated correction note at the end of the article.

Article: Qualified Person salaries in Irish biopharma

What was wrongThe headline said Irish biopharma pays up to €180,000 to retain Qualified Persons, and the pay table was higher than published 2026 recruiter guides. The article said QP status requires a master's degree and registration; the HPRA sets four routes to eligibility and there is no QP register. It also overstated the number of Irish facilities.
What we changedChanged the headline to Qualified Person (QP) Salaries in Irish Biopharma in 2026, replaced the pay figures with the HERO and Morgan McKinley ranges, corrected the requirements and used IDA Ireland's figures for facilities. Added a list of the sources used and a dated correction note at the end of the article.

Article: Community pharmacies and direct delivery

What was wrongThe article said online mail-order supply of prescription medicines is allowed in Ireland for registered community pharmacies. It is not: the HPRA says it is illegal to sell prescription medicines online in Ireland. The article also misdescribed electronic prescription records, the Common Conditions Service and the medicines optimisation changes, and carried an unattributed quote.
What we changedCorrected the legal position throughout with the HPRA's words, changed the headline to say direct delivery is growing in the UK, corrected the other details and removed the quote and unsourced claims. Added a list of the sources used and a dated correction note at the end of the article.

Article: GLP-1 research updates

What was wrongThe article described ACHIEVE-3 as including an obesity group without diabetes, with 13.6% weight loss at 40 weeks; it was a 52-week trial in adults with type 2 diabetes. It gave a 73% knee pain reduction from a FORTH trial (the result is retatrutide's TRIUMPH-4, up to 75.8%), confused orforglipron with its brand name Foundayo, and overstated a mouse brain study.
What we changedCorrected the trial details, the naming and the description of the study, added trial dates and removed unsourced figures. Added a list of the sources used and a dated correction note at the end of the article.

Article: Using LLMs safely in pharma

What was wrongThe guide presented its five rules and risk matrix as if they were a regulator's framework and described company policy as law. It did not say that EMA's GMP Annex 22 on artificial intelligence is still a draft.
What we changedLabelled the rules and matrix as recommended practice, cited draft Annex 22 as a draft, and reworded the legal claims. Added a list of the sources used and a dated correction note at the end of the article.

Article: OpenAI's Dublin Docklands office

What was wrongThe article carried a quote credited to an OpenAI announcement that we could not trace to OpenAI. It also gave details of the building, roles and headcount, such as 800 workstations and 350 staff by 2028, that we could not source.
What we changedReplaced the quote with a published statement from Emma Redmond, Head of OpenAI Ireland, removed the unsourced details, and added an update on the 200 extra jobs OpenAI announced on 12 October 2026. Added a list of the sources used and a dated correction note at the end of the article.

Article: AI in pharma, H1 2026 report

What was wrongThe article gave the value of Insilico's Takeda deal as undisclosed (it is about 600 million dollars in potential payments) and its Bora deal as over 2.5 billion dollars (the value was not disclosed), and presented the Lilly and SK figures as deal values when they are mostly milestones. Its Isomorphic, BMS, Roche, Lilly-NVIDIA and rentosertib details did not match the releases.
What we changedCorrected the deal values and the other details to match the companies' releases, and removed unsourced figures and an untraceable closing quote. Added a list of the sources used and a dated correction note at the end of the article.

Article: Water, power, data centres and life sciences in Ireland

What was wrongThe article used an older figure for data centres' share of electricity (the CSO gives 23% for 2025), said data centres matched urban homes in 2023 (21% against 18%), gave water leakage as 37% (it is 35.1%), said pharmaceutical plants use three to five times as much water as data centres (about 2.4 times) and described an EirGrid moratorium that no longer applies.
What we changedCorrected these figures, described the CRU's December 2025 connection rule and the FLAP-D markets correctly, and removed unsourced claims. Added a list of the sources used and a dated correction note at the end of the article.

Article: Quantum 2030, Ireland's quantum strategy

What was wrongThe article presented Quantum 2030 as a new strategy, although it was launched on 15 November 2023. It misdescribed the strategy's pillars, did not say that Science Foundation Ireland is now part of Research Ireland, and named a National Advisory Forum for Quantum Technology that we could not find.
What we changedAdded the launch date and reframed the article as background, corrected the pillars and the funder, and removed the unsourced claims. Added a list of the sources used and a dated correction note at the end of the article.

Article: US pharma resume guide

What was wrongThe guide said EEOC rules require candidates to leave photos and personal data off a resume. This is US convention; EEOC guidance is aimed at employers. It also presented page lengths as rules, did not label its sample bullet points as illustrations, and made unsupported claims about our own CV tool, such as EEOC compliant and ATS verified.
What we changedCorrected the EEOC statement, described page lengths as conventions, labelled the examples as illustrations and removed the claims about our tool. Added a dated correction note at the end of the article.

Article: UK pharma CV guide

What was wrongThe guide said the Equality Act 2010 requires candidates to leave a photo off a CV. This is UK convention, not a legal requirement. It also presented page lengths as rules, applied distribution guidelines (GDP) to QC testing, which falls under manufacturing guidelines (GMP), and did not label its sample bullet points as illustrations.
What we changedCorrected these points and removed an MHRA Aligned label. Added a dated correction note at the end of the article.

Article: TechIreland National AI Challenge 2026

What was wrongThe article still invited readers to register although the event has finished. It named CeADAR as a co-host; the organiser is TechIreland, supported by Enterprise Ireland and the European Digital Innovation Hubs Network. It gave timeline dates and regional hubs we could not confirm, and it published two staff members' personal email addresses.
What we changedRemoved the registration links and marked registration as closed, rewrote the headline, corrected the organisers, and removed the unconfirmed details and the email addresses. Added a list of the sources used and a dated correction note at the end of the article.

Article: Cross-border pharma CV guide

What was wrongThe guide said CV Studio templates are compliant with Workday and Taleo, recruiter-tested and formatted to HPRA, MHRA and FDA standards. We had not tested these claims. It also presented CV length and photo practices as rules when they are conventions.
What we changedRemoved the untested claims and described length and photo practices as conventions. Added a dated correction note at the end of the article.

Article: GEODIS Manchester pharma hub

What was wrongThe article gave details that are not in the GEODIS release: a Sharston Green location, ultra-low-temperature freezers, backup generators, humidity monitoring and a licence granted by the MHRA. It left out the scheduled go-live date and gave Irish pharmaceutical exports as €139 billion (the CSO figure is €138.6 billion).
What we changedRewrote the description to follow the GEODIS release of 6 May 2026, added the scheduled go-live date of 1 June 2026 and corrected the export figure. Added a list of the sources used and a dated correction note at the end of the article.

Article: ABPI impact map

What was wrongThe article reworded a quote from Joe Edwards and added a sentence he did not say. It described specialisms for each UK nation, an ABPI resilience framework and Irish supply-chain links that the sources do not support, including a passage that referred to an Irish NHS, and misdescribed the Northern Ireland jobs figure.
What we changedRestored the exact quote, removed the unsupported claims, corrected the Northern Ireland description and the Irish export figure (€138.6 billion, CSO), and changed the headline. Added a list of the sources used and a dated correction note at the end of the article.

Article: Ireland and EU pharma CV guide

What was wrongThe guide said 14 of the world's top 15 biopharma companies are in Ireland; IDA Ireland gives 14 of the top 15 medtech and 9 of the top 10 pharma companies. It listed Boston Scientific as biopharma (it is a medtech company), claimed an untested 99%+ ATS score for our templates, and presented CV length and photo practices as legal rules.
What we changedCorrected the IDA figure and the description of Boston Scientific, removed the ATS claim and described length and photo practices as conventions. Added a dated correction note at the end of the article.

Article: UK-India CETA and pharmaceutical value chains

What was wrongThe article said Indian active ingredients faced UK tariffs of 7.5% to 12.5%; UK duties on most medicines were already 0%. It said the agreement created GMP mutual recognition between the MHRA and CDSCO; it contains none. Three charts and a 15% cost saving had no traceable source.
What we changedRewrote the affected sections around the actual tariff and inspection position, removed the three charts and the 15% figure, and described the likely effect on NHS prices as limited. Added a list of the sources used and a dated correction note at the end of the article.

Article: Ireland-India pharmaceutical corridor

What was wrongThe article attributed the phrase mother of all deals without support, said the UK-India agreement contains GMP mutual recognition (it does not), and gave the 96.6% tariff figure by tariff lines rather than by value. It also misstated the Irish export and US-share figures, the vaccine share, and the shares of active ingredients from China and India.
What we changedCorrected these figures to European Commission, CSO and CMA sources, removed unsourced timeline claims, added that the Commission sent the agreement to the Council on 11 September 2026, and labelled the €17.7 billion trade base as unconfirmed. Added a list of the sources used and a dated correction note at the end of the article.

Article: UK-India free trade agreement

What was wrongThe article said the agreement includes mutual recognition of GMP standards and inspections; it does not. It said Indian tariffs on medical devices are eliminated (the UK government says reduced), understated car tariffs before the deal (over 100%), presented doubling trade by 2030 as a projection rather than a political target, and gave unchecked tariff ranges.
What we changedCorrected these points, removed the unchecked ranges and added the UK government's own estimates of the deal's gains. Added a list of the sources used and a dated correction note at the end of the article.

Article: Dutch innovative pharma and cost control

What was wrongThe article changed the wording of quotes from Diederik Stadig, did not credit Rapporteur (Euractiv) or say that its coverage is supported by EFPIA, gave a year for Dutch production figures that the source does not give, and described price-control proposals and VIG lobbying that the source does not mention.
What we changedRestored the exact quotes, credited the source and its EFPIA support, removed the year and the unsupported claims, and changed Defense to Defence in the headline. Added a list of the sources used and a dated correction note at the end of the article.

Article: EU seeks US tariff exemptions for medical devices and spirits

What was wrongThe article gave the EU exemption list a value of €150-155 billion; an EU official put it at about €150 billion and AFP at about €115 billion. It carried a sector breakdown, chart, table and quote with no source, said Scotch whisky (a UK product) was on the EU list, and said the list was presented at talks in Washington.
What we changedGave the value from both sources, removed the unsourced material and the whisky and Washington claims, separated pharmaceutical tariffs from the device list, changed the headline and replaced the old source list. Added a list of the sources used and a dated correction note at the end of the article.

Article: Pilot Photonics EIC Accelerator funding

What was wrongThe article named Frank Smyth as CEO and William Oppermann as the founder of MBRYONICS; Oppermann is Pilot Photonics' CEO and Smyth its CTO. It gave Minister Peter Burke's title as Enterprise, Trade and Employment (it is Enterprise, Tourism and Employment) and carried a quote and technical claims we could not source.
What we changedCorrected the names, roles and title, removed the quote and the unsupported claims, and added the 3 July 2026 announcement date. Added a list of the sources used and a dated correction note at the end of the article.

Article: Ireland's goods exports in May 2026

What was wrongThe article gave the May 2025 pharmaceutical export base as €13.6 billion and called it a record; the CSO gives €13.5 billion and calls nothing a record. It gave imports from Great Britain as €1.9 billion (the CSO says €1.39 billion), said chemical imports drove the rise in imports when they fell, and added unsourced commentary.
What we changedCorrected the figures, changed the headline, and removed the commentary on stockpiling timing, domestic demand and the fiscal outlook. Added a list of the sources used and a dated correction note at the end of the article.

Article: MGS Mfg. Group Leixlip expansion

What was wrongThe article quoted MGS in words that go beyond the source, gave the CEO's tenure as over 25 years (he joined MGS in 1996 and has been CEO since 2020), listed the wrong MGS sites and said ISO 13485 certification guarantees safety. It also gave site and extension sizes that do not match, and unsourced equipment and demand details.
What we changedCut the quote back to the source, corrected the tenure and the sites, noted that the reported sizes do not match, reworded the ISO text and removed the unsourced details. Added a list of the sources used and a dated correction note at the end of the article.

Article: Irish EU Presidency and the Biotech Act

What was wrongThe headline described a €10 billion Biotech Act. The €10 billion is the separate BioTechEU initiative, a target for investment, not funding in the Act. The article carried a quote we could not trace, called the Minister newly appointed, said the Directive covers tissues and cells, and gave industry figures we could not source.
What we changedChanged the headline, described BioTechEU separately, replaced the quote with the Department of Health's published words, named the 12-month SPC extension and removed the unsourced figures. Added a list of the sources used and a dated correction note at the end of the article.

Article: Ireland's medicine access delays

What was wrongThe headline gave an 801-day wait for new medicines in Ireland, a figure we could not find in the EFPIA report or any other source. The article gave the EU average as 614 days (597 in the 2025 W.A.I.T. data; EFPIA's median is 532) and Germany as 127 days (EFPIA gives 56), and cited orphan-drug reimbursement percentages with no source.
What we changedChanged the headline to Ireland's Medicine Access Delays and the Case for Reform, replaced the figures with sourced ones, removed the unsourced percentages and review claim, and added the planned early access pilot for rare diseases. Added a list of the sources used and a dated correction note at the end of the article.

Article: Intel's Leixlip investment

What was wrongThe article called Micheál Martin the Tánaiste; he is the Taoiseach. It extended quotes beyond the words in the sources, gave the Pentium launch year as 1994 (it was 1993), and included unsourced remarks, figures and technical claims.
What we changedCorrected his title throughout, including captions, cut the quotes back to the sources, corrected the year, removed the unsourced material and added the sourced construction details. Added a list of the sources used and a dated correction note at the end of the article.

Article: University of Galway Rinn medical devices centre

What was wrongThe article called the funding one of the largest investments in Irish research history and Galway a top-five global MedTech hub, neither of which is sourced. It gave the number of institutions partnering on all seven centres as both three and two, gave the wrong focus and an invented funding split in its FAQ, and showed the FAQ twice.
What we changedRemoved the unsourced claims, clarified the institution count, corrected the FAQ answers and removed the duplicate FAQ. Added a list of the sources used and a dated correction note at the end of the article.

Article: B2B pharma and Generative Engine Optimization

What was wrongThe article made unsourced claims about how AI search engines and LinkedIn's algorithm rank content, cited unnamed research, gave an unsourced 5-8 times reach multiple for personal profiles, and stated LinkedIn's 30% figure as fact when LinkedIn says potentially. A Waterford example read as real but was invented.
What we changedRemoved or reworded these claims, credited the GEO term to Aggarwal et al. (2023), attributed the 30% figure to LinkedIn and marked the example as invented. Added a list of the sources used and a dated correction note at the end of the article.

Article: Phantom exports and Irish GDP

What was wrongThe article included a chart and contract manufacturing totals that we could not trace to CSO data. It dated the export surge to late 2025 (it was Q1 2025), gave growth in modified domestic demand as 2.4% (the CSO says 4.9%), defined GNI* wrongly and described how contract manufacturing is recorded the wrong way round.
What we changedRemoved the chart and the totals, corrected the timing, the growth figure, the GNI* definition and the FAQ, and added sourced CSO context. Added a list of the sources used and a dated correction note at the end of the article.

Article: Chanelle Pharma and the Galway Races

What was wrongThe article carried a quote from Galway Racecourse that did not match the official release and extended the Chanelle Pharma quote beyond the source. It gave Michael Burke a role in March 2026 that no source supports, named a race we could not verify, and gave attendance as over 100,000 (the release says over 130,000 across the week).
What we changedReplaced the quotes with the published words, corrected Michael Burke's role and the attendance figure, and removed the unverified race name and festival dates. Added a list of the sources used and a dated correction note at the end of the article.

Article: Newsletters for pharma companies

What was wrongThe article gave a pharma email open rate of 35-42% and other reach and growth figures with no source, and cited a Mailchimp benchmark report for 2026 that does not exist. It said GDPR requires double opt-in, which it does not, and described tracking individual readers by name without a privacy caveat.
What we changedReplaced the figures with Mailchimp's published benchmarks, corrected the GDPR statement, added a consent and transparency caveat, softened unchecked platform claims and removed an unlinked sources line. Added a list of the sources used and a dated correction note at the end of the article.

Article: LinkedIn brand-building playbook

What was wrongThe guide gave LinkedIn's membership as one billion (it is more than 1.4 billion) and out-of-date logo and banner sizes. It presented reach, link-penalty and posting-time figures as LinkedIn data, when they are not official LinkedIn figures.
What we changedUpdated the member count and image sizes from LinkedIn Help, removed the unofficial figures and removed an unlinked sources line. Added a list of the sources used and a dated correction note at the end of the article.

Article: NHS fast-track medicines pilots

What was wrongThe article said the pilots were scheduled to begin in September 2026; DHSC says testing could begin as early as September. It said legal challenges had been started, when the groups had sent a pre-action letter and were seeking permission for judicial review. It misstated the DHSC response and carried an unattributed quote and several unsourced claims.
What we changedCorrected the start date, the stage of the legal challenge and the DHSC response, and removed the quote, the unsourced claims and an unlinked sources line. Added a list of the sources used and a dated correction note at the end of the article.

Article: Eli Lilly's Foundayo launch

What was wrongThe article gave Jefferies sales estimates of 71 and 85 million dollars, a 130 million dollar consensus and about 20,000 weekly prescriptions, none of which we could verify, and quoted an unnamed endocrinology specialist.
What we changedRemoved the estimates, the prescription figure and the quote, used the confirmed early prescription data, and added an update with Lilly's reported second-quarter Foundayo revenue of 98 million dollars. Added a list of the sources used and a dated correction note at the end of the article.

Article: Xylo pre-seed round

What was wrongThe article carried two quotes that do not appear in any source. It misstated the investor list, overstated Xylo's results, described the company as working in the UK and Ireland (it works in the UK), and made unsourced claims about product features. One section appeared twice.
What we changedRemoved the quotes, corrected the investors and the results, which are now attributed to Xylo, and removed the unsourced claims and the repeated section. Added a list of the sources used and a dated correction note at the end of the article.

Article: Tapestry VC Fund III

What was wrongThe article carried three quotes that do not appear in any source. It misstated the cheque sizes (up to 3 million dollars, according to Tech.eu) and described the British Business Bank as a 40 million dollar co-anchor, when it made a cornerstone commitment of up to 40 million dollars. A block of FAQs appeared twice.
What we changedReplaced the quotes with verbatim quotes from Audrey Miller and Patrick Murphy, corrected the figures, and removed the unsourced claims and the repeated FAQ block. Added a list of the sources used and a dated correction note at the end of the article.

Article: NeuroBell funding for Luna

What was wrongThe article carried two quotes that do not appear in any source. It said NeuroBell was founded in 2023 (it was spun out of University College Cork in January 2024), overstated the research history and Parkview Health's role, answered wrongly in its FAQ who led the round, and gave an unsourced incidence figure.
What we changedReplaced the quotes with verbatim quotes from CEO Dr Mark O'Sullivan and Niall McEvoy of Elkstone, corrected the dates, Parkview's role and the FAQ (Elkstone led the round), removed the figure and said FDA clearance has not yet been granted. Added a list of the sources used and a dated correction note at the end of the article.

Article: Build seed round

What was wrongThe article carried two quotes that do not appear in any source, an unverified product name and a wrong euro figure for the 8.5 million dollar round. Several sections, some of them repeated, described a different product.
What we changedReplaced the quotes with verbatim quotes from co-founder James Stirrat-Ellis and Martin Mignot of Index Ventures, removed the unverified details and the sections about the other product, and added sourced company facts. Added a list of the sources used and a dated correction note at the end of the article.

Article: Chanelle McCoy Health and Pureis CBD

What was wrongThe headline and text presented Saudi and European regulatory approvals as fact, naming EFSA and the European Commission, when only the company has reported them, and no CBD novel food is authorised in the EU. The article also reworded Chanelle McCoy's quote and made unsourced and promotional claims, such as first and only.
What we changedChanged the headline to say the company reports Saudi approval, attributed the claims to the company, described the EU position, replaced the quote with her verbatim words and removed the unsourced claims. Added a list of the sources used and a dated correction note at the end of the article.

Article: Top 10 technical and GMP trends for 2026

What was wrongThe article said the EU Pharmaceutical Package was in full enforcement; political agreement was reached on 11 December 2025 and adoption is pending. It presented the FDA's CSA guidance as general GMP guidance (it covers medical device software), described FDA quality metrics as final guidance, said real-time release testing frees batches automatically, and gave unsourced percentages.
What we changedCorrected these points, noted that a Qualified Person must still certify batches in the EU, and removed the unsourced figures. Added a list of the sources used and a dated correction note at the end of the article.

Article: Common Technical Document structure

What was wrongA block of frequently asked questions appeared twice on the page. We found no factual errors.
What we changedRemoved the repeated block and merged the distinct questions under one heading. Added a list of the sources used and a dated correction note at the end of the article.

About, Contact, Privacy policy and Terms of use

What was wrongThe Contact page gave our location as County Limerick, while the About page says our founder is based in Dublin. The About page still listed "Community Owned" among our values, although Priya Life Science is owned and run by its founder. The Privacy policy said our registered address was in Section 13, but that section gave only an email address, and no page said who publishes the site.
What we changedThe Contact page now says Dublin, Ireland. The value is now "Community Driven": owned and run by our founder, built with and for the community. The Contact page, Privacy policy and Terms of use now name the publisher and data controller, Sreepriya Prasannan, Dublin, Ireland, and the Privacy policy no longer refers to a registered address.
To prevent itLocation, ownership and publisher details now use one wording, and every page is searched for the old wording before a change to them is published.

Site footer (every page)

What was wrongThe footer on every page said "Est. 2023". Priya Life Science was founded in 2025 and its website launched in 2026, as the About and Editorial standards pages say.
What we changedThe footer now says "Est. 2025". The same update refreshed the LinkedIn figures in the footer and on the About, Advertise and home pages to the 365-day LinkedIn analytics view taken on 30 October 2026.
To prevent itBefore any page change is published, the whole site is searched for founding years and audience figures, so an old figure cannot survive in a template.

Article: SK Biopharmaceuticals and opakalim

What was wrongThe headline said SK Biopharmaceuticals acquires the epilepsy candidate opakalim. The deal is an exclusive worldwide licence from Biohaven, worth up to 795 million dollars, not an acquisition; the article text already described it as a licence.
What we changedChanged the headline to say SK Biopharmaceuticals licenses opakalim.

Article: AbbVie and Apogee Therapeutics

What was wrongThe article, published on 19 June 2026, said AbbVie was nearing an 11 billion dollar acquisition of Apogee Therapeutics, based on reports at the time. AbbVie later agreed the deal and completed it on 3 September 2026 for about 10.9 billion dollars, and the article had not been updated.
What we changedUpdated the headline, summary and description, and added a dated update note at the top with the completion date and price from AbbVie's SEC filing. The original report below the note is unchanged.

About and Editorial standards

What was wrongOur pages contradicted each other. The Editorial standards page said Priya Life Science was founded in 2023, while the About page said 2025. The About page also said articles get a light editorial review, while the Editorial standards page said every article is reviewed, verified and approved by a human editor, and it described the site as owned by the community.
What we changedBoth pages now give the same facts: founded in 2025, website launched in 2026, owned and run by the founder and built with and for the community, and every article reviewed, verified and approved by a human editor before publication. The same wording is used in the email sent to contributors.
To prevent itThese facts are kept in one agreed wording, and every page is searched for the old wording before a change to them is published.

Articles: Fleming Corporate Compliance and Transparency summit, Zurich

What was wrongTwo articles about the Fleming Events summit in Zurich, where Priya Life Science is a media partner, were published like news. One carried the labels "Editorial Verification" and "Peer Reviewed & Fact-Checked" and said it was "verified in partnership with Fleming Events". Both include a reader discount code. Priya Life Science does not peer review articles, and neither piece said it was promotional.
What we changedBoth articles now open with a label saying they are media-partnership promotional content, not independent news, and not peer reviewed. The "Peer Reviewed & Fact-Checked" and "Editorial Verification" labels were removed. The second article is at /article/ai-governance-corporate-compliance-transparency-life-sciences-zurich-2026.
To prevent itEvery article now carries a label under the byline (News, Career guide, Contributed or Partner content), set automatically, so partner content always shows as such. We do not use "peer reviewed" on any article.

Advertise with us

What was wrongThe page said we reach 340,000+ pharma and life science professionals and called our reach our own. Most of that reach is on the personal LinkedIn profile of our founder, not all of it is professionals in the sector, and the 340,000 figure came from a LinkedIn screen whose period we had not confirmed with an export. The page also offered sponsored content that "reads naturally alongside our editorial", and the sidebar called us "Ireland's largest life science community", which we cannot show.
What we changedThe page now gives the figure from the LinkedIn audience export (269,076 members reached, 15 July 2025 to 14 July 2026) and says it comes from our founder's profile. It says sponsored and partner content is always labelled and kept off medicine pages, and the sidebar no longer says "largest".
To prevent itA figure goes on the Advertise page or in the footer only if it can be reproduced from a dated analytics export, and LinkedIn and website figures are never added together.

Data report: Clinical trials in Ireland, the numbers behind 2,691 studies

What was wrongOn the day it was published, the report said most studies open to new participants are Phase 3 or late-phase; in fact 185 of the 360 open studies have no phase, and 117 of the 175 that do are Phase 2/3 or later. It also said trial activity is concentrated in five hospitals that host the great majority of industry sites, a figure we had not calculated, and its status table left out 21 studies (12 suspended and 9 expanded-access records), so its rows added up to 2,670 rather than 2,691.
What we changedCorrected the phase sentence to the counts above, replaced the hospital sentence with the seven hospitals each listed on more than 120 studies, added the three missing statuses to the table, and reworded the sponsor-class sentence so research networks are not counted twice. The archived PDF of record was made from the corrected text.
To prevent itA data report is archived with a DOI only after a human editor has approved the checked text; until then the archiving job skips it.

Article: Leah Fletcher named HPSU Founder of the Year

What was wrongThe article said Enterprise Ireland announced the award on 16 October 2026, and its timeline and FAQ gave 16 October as the date Leah Fletcher was named Founder of the Year. She was named the winner at the awards ceremony at Salesforce Tower, Dublin, on the evening of Thursday 15 October 2026; the Enterprise Ireland press release is dated 16 October. The article also said around 500 companies had taken part in the HPSU Founders Forum, where Enterprise Ireland gives the figure as 500.
What we changedCorrected the date in the text, timeline and FAQ to 15 October 2026, with the press release date given as 16 October, changed the figure to 500, and added a dated correction note to the article.

PDF tools: redaction

What was wrongOur guide on redacting PDFs said Redact PDF removes the content under a redaction, and the Find and Redact and Sensitive Data Redaction pages said the covered text is permanently removed or erased. A review of the code found that these tools draw opaque boxes over the text and that the text underneath stays in the file.
What we changedThe guide and the three tool pages now say the boxes cover the text and do not delete it, and explain how to remove it: convert the boxed file with Rasterize PDF, which rebuilds each page as an image, then search the result to confirm.

PDF tools: Timestamp PDF

What was wrongThe Timestamp PDF page promised RFC 3161 trusted timestamps from timestamp authorities such as DigiCert and Sectigo, and two blog articles said the tool sends a hash of the document to the authority you choose. The tool contacts no timestamp authority: it records the device clock time and signs with a certificate generated in the browser.
What we changedThe tool page now explains what the tool does and that it is not a trusted timestamp or proof of when a document existed, the page is no longer offered to search engines, and the two articles were corrected.

PDF tools: electronic signatures article

What was wrongThe article said Regulation (EU) 2024/1183 did not change Article 25 of eIDAS and cited Article 25(3) for the cross-border recognition of qualified electronic signatures. The amendment deleted Article 25(3) and moved that rule to a new Article 24a(1).
What we changedCorrected the passage and added a dated correction note to the article.

PDF tools (pdf.priyalifescience.com)

What was wrongEvery tool page and the footer said the tools comply with GDPR Article 25 and the Irish Data Protection Act 2018 and have a "GxP Pharma Compliant Architecture", and the homepage listed EU GMP Annex 1, FDA 21 CFR Part 11, HPRA and ICH Q10 as frameworks the tools were "trusted for". These were claims of compliance we cannot make for general-purpose software. The contact page also listed an email address, a GitHub account and a social account that do not exist, and its form showed "Message sent" without sending anything.
What we changedRemoved the compliance claims and replaced them with what is true: files are processed in the browser and not uploaded. The contact page now gives info@priyalifescience.com, the real GitHub repository and LinkedIn page, and the form opens your email app with the message ready to send.

Regulatory news

What was wrongAlongside the EMA's official feed, the page showed 14 items written into the page itself and presented as HPRA and EMA notices from May and June 2026, among them HPRA recalls, an HPRA notice on insulin pumps and CHMP recommendations. 13 of their 14 links led to pages that do not exist on hpra.ie or ema.europa.eu, and none could be traced to a published notice. The page also promised HPRA warnings and real-time updates, which it never had.
What we changedRemoved all 14 items. The page now shows only what the EMA publishes in its What's new feed, refreshed every 6 hours, with the source named on the page; it no longer claims HPRA alerts and links to the HPRA website instead.
To prevent itFeed pages show only items fetched from the named source. When a feed returns nothing, the section is hidden rather than filled with stand-in items.

Market data

What was wrongThe page credited Twelve Data as the source and described the figures as end-of-day closing prices refreshed every 30 minutes. The prices come from Yahoo Finance, they are the latest delayed price rather than the closing price, and they refresh every 15 minutes.
What we changedCorrected the source to Yahoo Finance and described the prices as they are: delayed, in US dollars for the US listings, refreshed every 15 minutes, with the daily change measured against the previous close.
To prevent itMarket widgets now hide when the price feed returns nothing, instead of showing stand-in figures.

Ireland pharma map

What was wrongA pin-by-pin check of all 411 sites found 24 pins in the wrong place, among them ProAxsis (shown in Antrim town instead of the Titanic Quarter, Belfast), West (shown in central Dublin instead of Damastown), Zoetis, Jabil, Antylia (on the county centre instead of Mullingar), Phyxiom and Maperath Herbal; several pins labelled as exact sites, such as Sanofi and AbbVie, were more than half a kilometre from the plant.
What we changedMoved the 24 pins to the published address of each site, located via OpenStreetMap, and relabelled their precision honestly. Pins whose position could not be confirmed this way are listed for a check by hand.
To prevent itEvery pin now records its source and how precise it is (site, business park or town). Coordinates are never imported in bulk from a search engine; each one is checked against a published address.

Ireland pharma map

What was wrong143 organisations shared a pin with others because only their town was known: 46 sat on one point in Dublin city centre, 15 on one point in Galway, and others in Belfast, Cork, Little Island, Waterford, Kilkenny, Dundalk and Clonmel. Several pins labelled as exact sites were in the wrong place, among them the two Janssen sites (pinned at Carrigaline instead of Ringaskiddy) and Integer, formerly Aran Biomedical (pinned at Parkmore instead of Spiddal).
What we changedLooked up the published address of each organisation and moved 103 pins to their building, business park or street using OpenStreetMap, each with the source of the address. The largest shared point now holds 10 organisations, most of which publish only a registered office; those stay at town level and say so.

Ireland pharma map and State of Irish Life Sciences

What was wrongBoth pages described the list of manufacturing sites and its employee counts as compiled by our desk from IDA Ireland, company and planning material. The original 213-site list and every headcount came from the public GetReskilled list of pharmaceutical and medical device factories in Ireland, and the headcounts carry no date. The map also stated a Creative Commons licence over the whole dataset, and the quarterly report gave one employment total as if it covered every facility.
What we changedGetReskilled is now credited wherever a headcount appears: on the map, in each pin, in the sources section, in the downloadable file and in the citation. The licence statement was removed, and the employment total now says how many sites it covers.

Ireland pharma map

What was wrongA site-by-site check of 301 manufacturing sites found errors on the map. The Vantive plant in Swinford was pinned on the Castlebar plant; the Stryker sites at Macroom and Model Farm Road and the Viatris plant in Baldoyle shared the pin of another site of the same company; 17 pins labelled as exact sites were more than 1.5 km from the plant (among them MSD Carlow, MSD Ballydine, Lilly Limerick and LEO Pharma Dublin); Dunbar Pharma and Arran Chemical, both at Monksland, were listed under Westmeath instead of Roscommon, and Pinewood Healthcare under Tipperary instead of Waterford; Connexicon Medical linked to the ICON plc profile; four companies appeared twice; 11 manufacturing plants were shown as research or service companies; and 107 verified manufacturing sites were missing.
What we changedMoved or relabelled 76 pins using OpenStreetMap, so a pin now says whether it marks the site, its business park, or only its town; corrected the three counties; removed the wrong profile link and the four duplicates; reclassified the 11 plants; and added the 107 missing sites, each with the source it was checked against. Pins that are still approximate say so and are being checked by hand.

Article: Leading CDMO Companies in Ireland

What was wrongA fact-check of 107 claims found 28 wrong, 6 outdated and 21 that could not be verified. The guide listed Wasdell's Dundalk plant, which closed in 2024; placed Thermo Fisher's Cork site in Ringaskiddy instead of Currabinny; described Hovione's equipment with text that belonged to another company; used an outdated tax rate (12.5% and a 6.25% Knowledge Development Box); ranked Ireland third in the world for pharma exports; and labelled sites "FDA approved", which the FDA does not do for facilities.
What we changedRemoved Wasdell (the guide now covers eight companies), corrected locations, figures, dates and ownership to published sources, replaced "FDA approved" with the regulator that actually licenses or inspects each site (HPRA, MHRA, FDA inspection), updated the Ireland facts (CSO exports of €138.6bn in 2025, 15% tax for large groups, 10% KDB), removed claims we could not confirm, and added the sources used. A correction notice sits at the top of the article.

Funding tracker

What was wrongThe header showed three figures with no stated source: "€2.1B+ Irish pharma exports monthly", "300+ life science companies in Ireland" and "90+ global pharma firms with Irish operations". The exports figure was well below the CSO's published monthly value.
What we changedReplaced with figures calculated from our own registers: the latest month of Irish pharmaceutical exports from CSO table TSM09 (€6.9bn in July 2026), and the number of Irish-registered companies of the groups in our company financials register (263, across 51 groups), each linked to its source.

Molecule lookup

What was wrongThe canonical SMILES field showed "N/A" for every molecule, because PubChem had renamed the property the page requested.
What we changedThe page now requests PubChem's current property (ConnectivitySMILES) and shows the value again.

Ireland clinical trials dashboard and Ireland register

What was wrongThe ClinicalTrials.gov search used a free-text location match, which also picked up studies outside the Republic of Ireland, such as sites with "Ireland" in their name elsewhere and sites in Northern Ireland. The dashboard counted 3,146 studies, of which 456 had no site in Ireland.
What we changedThe search now filters on the location country field, and a study is counted only when it lists an Irish site. The dashboard now covers 2,691 studies; the Ireland trials register went from 616 to 603.

EU clinical trials register

What was wrong41 trials whose CTIS status is "Not authorised" were listed among authorised trials, and several CTIS status codes were labelled imprecisely.
What we changedTrials that were not authorised are no longer listed, and every status label now matches the CTIS status code it comes from.

Drug approvals worldwide, FDA biosimilars and patent expiry

What was wrongThree matching errors in the first-approval data: name cleaning shortened some two-word substances (for example epoetin alfa), so a 2018 biosimilar appeared as the first US approval; insulin glargine showed a 2015 approval as first instead of Lantus (2000); and 17 of 94 biosimilars had no approval date. A discontinued product also gave metformin a patent expiry in 2035.
What we changedCorrected the name matching and date parsing, and excluded discontinued products from patent data. Epoetin alfa now shows Epogen (1989), insulin glargine shows Lantus (2000), and every biosimilar has its date.

Company profiles

What was wrongAn accuracy check of 1,419 profile items (leadership, products, sites, milestones) against their cited sources found 14 that did not hold up, including product lists that were therapy areas rather than products and an Irish site that had since been sold.
What we changedCorrected 4 items and removed 10. Every remaining profile item links to the source it was checked against, with the date of the check.

CDMO directory

What was wrongThe directory listed a Wasdell facility in Dundalk that closed in 2024, and several profiles overstated employee numbers or facility sizes, gave wrong addresses (HiTech Health, Cambrex Waterford) or used an unsourced investment figure (WuXi Biologics).
What we changedRemoved the closed facility, corrected figures and addresses to published sources, and removed claims we could not confirm.